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Coronary heart disease (CHD) is the single largest killer of American females.  Prevalent risk 
factors that give rise to increasing coronary risk for women include markers of inflammation, 
such as C-reactive protein (CRP), lipid abnormalities, such as lipoprotein(a), and insulin 
resistance.  Also, rates of CHD are relatively low among premenopausal women but increase 
sharply with age and the onset of menopause.  The primary purpose of this study was to examine 
the associations between CRP and physical activity on the risk factor profile of postmenopausal 
women without known heart disease who were either taking or not taking hormone therapy.  The 
secondary purpose of this investigation was to examine the relation of other cardiovascular risk 
factors on subclinical measures of coronary heart disease CHD.  A cohort of 201 
postmenopausal, 52-62 year old women who are enrolled in the Women On the Move through 
Activity and Nutrition (WOMAN) Study was examined at the baseline evaluation.  Spearman 
correlations revealed a significant inverse relationship between CRP and mean pedometer steps 
(rho= -0.2441, p=0.0348).  Significant positive correlations were identified between CRP and 
body mass index (rho= 0.3081, p<0.0001), waist circumference (rho= 0.25711, p<0.0002), and 
triglycerides (rho= 0.1925, p=0.0063).  Women taking hormone replacement therapy had 
significantly higher levels of CRP (p=0.0216) than those women not on hormone therapy.  There 
was no significant relationship found between CRP and intima medial thickness, nor with 
coronary artery calcium score.   The women identified with metabolic syndrome by ATPIII 
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guidelines had significantly lower HDL-cholesterol levels (p<0.0001) and higher total 
cholesterol (p=0.0072), triglycerides (p<0.0001), glucose (p<0.0001), and insulin (p=0.0183) 
levels.  These women also had significantly higher body mass index (p=0.0210), systolic blood 
pressure (p<0.0001), carotid intimal medial thickness (p=0.0378) and coronary calcium score 
(p=0.0125).   
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1.0  THE PROBLEM 
1.1 Introduction 
The primary purpose of this study was to examine the associations between C-reactive 
protein (CRP) and physical activity on the risk factor profile of postmenopausal women without 
known heart disease who were either taking or not taking hormone therapy.  The secondary 
purpose of this investigation was to examine the relation of other cardiovascular risk factors on 
subclinical measures of coronary heart disease (CHD).  This chapter is separated into the 
following sections: (1) Rationale, (2) Statement of the Problem, (3) Significance of the Problem, 
(4) Specific Aims and Hypotheses, and (5) Summary. 
1.2 Rationale 
Coronary heart disease (CHD) is the single largest killer of American males and females.  
Although there has been a decreased trend in mortality observed in males, the gap between male 
and female deaths has increased dramatically (3).    The reasons for this gender disparity are not 
well understood.  Most epidemiological studies examining CHD have concentrated primarily on 
males but suggest that the risk factor profile in men and women differ.  Prevalent risk factors that 
give rise to increasing coronary risk for women include markers of inflammation, such as C-
reactive protein (CRP), lipid abnormalities, such as lipoprotein(a), and insulin resistance (106).  
Also, rates of CHD are relatively low among premenopausal women but increase sharply with 
age and the onset of menopause. 
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Coronary heart disease is increasingly being viewed as an inflammatory process.  
Previous research has suggested that there is a relation between the inflammatory process and 
atherosclerosis (39,54,81).  It is suggested that high sensitivity C-reactive protein, a marker of 
inflammation, becomes elevated with atherogenesis and therefore can aid in prediction of CHD 
risk (54).  Elevated levels of CRP have been associated with increased risk of cardiovascular 
disease in apparently healthy individuals (50,73,76).  It is well known that low to moderate levels 
of daily physical activity help reduce CHD by improving many of the major predisposing and 
conditional risk factors (41).  Individuals diagnosed with CHD tend to have a clustering of 
modifiable risk factors; therefore regular physical activity can contribute to primary prevention 
through metabolic and circulatory mechanisms.  There is also evidence that higher levels of 
physical activity are associated with lower levels of C-reactive protein (1,25).  Although, the 
physiological mechanism responsible for this pattern is unclear, one could hypothesize that 
physical activity reduces the risk of CHD by reducing or preventing the inflammatory process.   
Previous research examining the relation between physical activity and CRP levels has 
had limitations.  First, many studies lack a reliable measure of physical activity.  The larger 
epidemiological studies utilize self-reported levels of physical activity by multiple methods that 
make it hard to compare studies.  Secondly, some investigations did not control for potentially 
confounding variables that may have elevated baseline levels of CRP such as not excluding 
individuals with an inflammatory disease (i.e. rheumatoid arthritis, asthma, bronchitis, 
emphysema, cancer, or stroke), and the lack of adjusting for obesity among the subjects.   
Since most risk factors for CHD are modifiable, lifestyle changes could conceivably 
decrease the incidence of disease or at least slow the process.  However, little is known about the 
associations between physical activity and these newly emerging risk factors in postmenopausal 
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females.  The conceptual understanding of risk factor modification and the differences in risk 
between the genders is important from a public health perspective.  Since CHD is considered to 
be in part preventable, it is imperative to educate the public regarding lifestyle modification.  
 This investigation may provide additional evidence of the role physical activity has in 
the primary prevention of CHD in postmenopausal women.  In addition, this investigation may 
provide evidence of the relation between the traditional and non-traditional risk factors and the 
role of hormone replacement therapy in risk prediction.  Collectively, this information could 
change the public health approach to the primary prevention of coronary heart disease in women.  
1.3 Statement of the Problem 
The primary purpose of this study was to examine the associations between C-reactive 
protein (CRP) and physical activity on the risk factor profile of postmenopausal women without 
known heart disease who were either taking or not taking hormone therapy.  The secondary 
purpose of this investigation was to examine the relation of other cardiovascular risk factors on 
subclinical measures of coronary heart disease (CHD).  
1.4 Significance of the Problem 
Coronary heart disease is considered a multifactorial disease because a wide array of 
variables is involved in the etiology of the disease.  For this reason, many clinicians find that risk 
assessment is an important tool to estimate the probability that individuals with certain risk 
factors will develop CHD.  This information may promote prevention and early treatment of the 
disease.  The longitudinal Framingham Heart Study has contributed significantly to 
cardiovascular research and risk factor analysis (18). 
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The Framingham Coronary Heart Disease Risk Score (FCRS) was created using a 
multiple logistic model and has identified risk factors for CHD. These risk factors are 
categorized as 1) major, 2) predisposing, or 3) conditional (105).  The major risk factors include: 
cigarette smoking, elevated blood pressure, elevated total and low density lipoprotein cholesterol 
(LDL), low serum high density lipoprotein cholesterol (HDL), the presence of diabetes mellitus, 
and age (103). The predisposing risk factors include: obesity, physical inactivity, family history 
of premature CHD, ethnic characteristics, and psychosocial factors.  Lastly, conditional risk 
factors include: elevated serum triglycerides, small LDL-C particle size, elevated serum 
homocysteine, elevated serum lipoprotein(a), prothrombotic factors, and inflammatory markers 
(103).  These conditional risk factors are associated with an increased risk for CHD yet there is 
not conclusive evidence of their causative, independent, and quantitative contributions to the 
disease state (27). 
Although widely perceived as an important clinical tool, the Framingham prediction 
model may not identify all persons at high risk for coronary heart disease.  Thus, many 
practitioners are including non-traditional risk factors, such as CRP, into their global 
cardiovascular disease risk prediction.  C-reactive protein levels have been shown to be 
significantly associated with the level of coronary heart disease risk as measured by the FCRS in 
men and women not taking hormone replacement therapy (4).  This research suggests that the 
conjunction of CRP and the FCRS may aid in the overall cardiovascular risk determination.   
The increased incidence of cardiovascular disease in women observed after menopause 
may be due to an estrogen deficiency.  Therefore, in the past women were being treated with 
estrogen replacement not only to decrease the symptoms of menopause but to also prevent 
cardiovascular disease.  However, this philosophy of treating women with hormone replacement 
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therapy (HRT) to prevent cardiovascular disease has been refuted based upon the results of 
clinical trials, specifically the Women’s Health Initiative (WHI).  According to an examination 
of national data on annual trends in hormone therapy in the United States, 42% of women aged 
50-74 years were taking HRT in 2001.  Following the release of WHI in 2002, a decline in HRT 
was observed with only 28% of women in the same age group using hormone therapy (34).  The 
new guidelines recommend against routine hormone therapy use for chronic conditions and 
current users have been advised to taper doses toward discontinuation (64, 92).    
Past research has suggested that hormone therapy can improve the overall lipid profile of 
postmenopausal women (30, 56, 80, 55).  Beneficial changes including a decrease in LDL-
cholesterol, and an increase in HDL-cholesterol have been observed.  Hormone therapy, 
however, has also been shown to increase triglyceride levels.  Triglycerides have been identified 
as an independent risk factor for CVD among women.  Despite the improvements of the lipid 
profile, hormone therapy has not been shown to be cardio-protective and in some cases HRT has 
been linked with an increased risk of heart disease.  Therefore, it is imperative to explore other 
strategies to decrease CHD risk in postmenopausal women.       
The association between cardiorespiratory fitness and CRP, and the effect of regular 
physical exercise training on CRP has been examined previously (20, 51).  The cardiorespiratory 
fitness level of a sample of men from the Aerobics Center Longitudinal Study was determined 
with a maximal treadmill test and CRP values were examined across the fitness levels (20).  
Statistical adjustments were made for body weight and within weight categories.  The 
researchers found that cardiorespiratory fitness levels were inversely related to CRP values.  This 
relation was independent of body weight.   
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LaMonte et. al (2002) assessed cardiorespiratory fitness, CHD risk factors, and CRP 
levels in a tri-ethnic (Caucasian, African, and Native American) sampling of women.  Significant 
correlations (p<0.05) were observed between CRP and fitness (r= -0.25), BMI (r=0.25), waist 
girth (r=0.21), insulin (r=0.26), and triglycerides (r=0.27).  The women who participated in this 
study were middle-aged, overweight, and had relatively low CHD risk factors.  The team of 
investigators concluded that aerobic fitness may reduce the risk of CHD in this population in part 
due to anti-inflammatory mechanisms (51).   
A few intervention studies have examined the direct effect of aerobic exercise training on 
CRP levels (61,91).  Mattusch, et al. (2000) found that nine months of extreme cardiovascular 
endurance training significantly decreased CRP levels (p<0.05) in male marathon runners.  
Fourteen, apparently healthy, moderately trained men participated in formal training sessions 3-4 
days per week.  The subjects ran continuously for 50 minutes at an intensity previously 
determined to be 75% of the speed at which their blood lactate concentration reached 4mmol/L.  
The researchers suggested that the decreased CRP levels observed in the runners may be due to 
the suppression of the inflammatory reaction (61).   
Another study conducted by Smith, et al. (1999), investigated the impact of a six-month 
exercise program on serum levels of CRP.   The 43 subjects (25 women and 18 men) included in 
this investigation had initial CRP levels which placed them at higher risk of developing ischemic 
CHD (91).  The subjects exercised at a hospital based wellness center where they completed a 
supervised and individually tailored exercise program.  On average, the subjects exercised for 2.5 
hours per week completing a program that consisted of cardiovascular training, weight lifting, 
and flexibility exercises.  The results of this investigation showed a clinically significant 35% 
decrease in CRP (p=0.12).   
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Therefore, since a relationship has been shown linking the direct measurement of 
cardiorespiratory fitness and CRP, we can make the assumption that regular leisure-time physical 
activity as reported by questionnaire should have the same effect on CRP.  Self-reported physical 
activity and CRP has been studied previously with varied conclusions.  More research looking 
specifically at postmenopausal women is needed. 
1.5 Specific Aims  
The specific aims of this study were to: 
1. Examine the relation between CRP and physical activity in postmenopausal women. 
2. To identify the factors that are related to CRP in postmenopausal women by using 
linear regression models with CRP value as the dependent variable and with physical 
activity and other cardiovascular risk factors as the independent variables. 
3. Determine the association between CRP levels and subclinical measures including 
coronary artery calcium score and carotid artery intimal thickness, as well as other 
cardiovascular risk factors in postmenopausal women.  
4. To determine the factors that are related to the coronary artery calcium score (CACS) 
in postmenopausal women by using a stepwise multiple regression model with CACS 
as the dependent variable and with physical activity and other cardiovascular risk 
factors as the independent variables. 
5. Identify subjects with characteristics of metabolic syndrome and determine if there 
are differences in CRP, CACS, carotid artery intimal thickness, and physical activity 
among women without metabolic syndrome. 
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1.6 Summary 
Coronary heart disease remains the largest cause of death among women and will 
continue to kill in large numbers as obesity coupled with a sedentary lifestyle become more 
common.  With this trend, prevalence of other elevated coronary risk factors may increase 
resulting in more individuals presenting with a clustering of risk factors.  Physical activity is 
critically important as it has been linked to a reduction in most major modifiable, predisposing 
and conditional coronary risk factors and thereby can ultimately aid in the reduction of the 
presence or severity of CHD.    
Clinicians have utilized the Framingham CHD risk profile score as a method of 
estimating the risk of future coronary events in both men and women.  Although an important 
clinical tool, not all individuals at high CHD risk are identified.  To improve this risk prediction, 
some other novel cardiovascular risk factors, such as CRP, have been considered as adjuncts to 
the primary prevention model.   
The emergence of CRP, a marker of inflammation, as a possible risk factor for 
cardiovascular disease has intrigued researchers.  While CRP has not been widely studied, the 
growing body of evidence suggests that there is an inverse relation between CRP levels with 
physical activity as measured by self-report.  However, there is less compelling evidence of the 
association in postmenopausal women.  Therefore, the primary objective of this study will be to 
investigate the relation between physical activity and resting CRP levels in postmenopausal 
women.       
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2.0  THE REVIEW OF RELATED LITERATURE 
2.1 Introduction 
The primary purpose of this study was to examine the associations between C-reactive 
protein (CRP) and physical activity on the risk factor profile of postmenopausal women without 
known heart disease who were either taking or not taking hormone therapy.  The secondary 
purpose of this investigation was to examine the relation of other cardiovascular risk factors on 
subclinical measures of coronary heart disease (CHD).  This chapter is separated into the 
following sections: (1) Women and CHD, (2) Risk Factors, (3) The Menopausal Transition (4) 
Hormone Therapy and Cardiovascular Disease, (5) Inflammation in Atherogenesis, (6) CRP and 
Cardiovascular Risk Prediction, (7) Physical Activity Assessment, (8) Physical Activity and 
Postmenopausal Women, (9) Physical Activity and CRP, (10) Cardiorespiratory Fitness and CRP 
(11) Subclinical Measurements, and (12) Summary. 
2.2 Women and CHD 
Cardiovascular disease is the leading cause of death among both men and women and 
claims more lives each year than the next five leading causes of death combined (3).  A common 
myth is that heart disease is a “man’s disease”.  However, the fact remains that cardiovascular 
diseases are devastating to women, too.  According to the American Heart Association (2002), 
cardiovascular diseases claim the lives of more than half a million females every year; about a 
death a minute.  Typically for females, CHD occurs later in life as compared to men and a 
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women’s risk dramatically increases after the onset of menopause.  Theoretically, the protective 
effect of estrogen acts to reduce cardiac risk by dilating the coronary arteries and decreasing 
platelet aggregation and fibrogen levels (12). Also, estrogen protects by raising HDL cholesterol 
levels and lowering LDL cholesterol levels.  As the female hormones decrease after menopause, 
the risk of coronary artery disease increases.   
Cardiovascular disease is progressive in nature and most diagnosed individuals will 
present with symptoms and a clustering of risk factors.  Frighteningly, according to the AHA 
(2002), 50% of men and 63% of women who died suddenly from CHD had no previous 
symptoms.  Thus, individual awareness of symptomology, family history, and cardiovascular 
screening is important to identify this disease early.  Cardiovascular disease is the leading cause 
of death and an important contributor to morbidity and disability among women.  This disease is 
largely preventable, and the epidemiology of this disease suggests that aggressive risk reduction 
including counseling about lifestyle on an ongoing process throughout a women’s life offers 
profound benefits.   Thus, it is important for physicians and health educators to be aware of 
gender differences in prevention of CHD and the interpretation of risk factors. 
2.3 Risk Factors 
Risk factors for CHD in women are well documented (62) and previous research has 
shown that early risk reduction may prevent CHD.  However, there are alarming trends in the 
prevalence and management of risk factors in women (62).  The prevalence of obesity is 
increasing, and women are more likely than men to not participate in regular sustained physical 
activity.  Smoking rates are declining less for women than men (87).  Approximately 22% of 
women aged 20 years and older have elevated serum cholesterol levels > 240mg/dL (87).  Also, 
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30% of females aged 35-44 years have elevated blood pressure readings of at least 140/90 
mmHg (19).   
Traditional risk factors for developing coronary artery disease in women can be 
categorized as those that are modifiable and those not modifiable.  The modifiable risk factors 
include: elevated LDL-C, HDL-C < 40 mg/dL, smoking, hypertension, body mass index, diet, 
and exercise.  Those risk factors determined to not be modifiable include: current age, family 
history, diabetes mellitus/insulin resistance, and age at menopause. 
The most common risk factor for CHD in women is a sedentary lifestyle.  National 
statistics show that 43% of females 18 years and older report no leisure-time physical activity 
with rates of physical inactivity the highest among minority women (87).  Only 20% of females 
over the age of 18 routinely engage in vigorous physical activity that promotes the development 
and maintenance of cardiorespiratory fitness (87).  Physical inactivity has been directly linked to 
higher rates of obesity and myocardial infarction (94).  The Nurses Health Study (1997) suggests 
that modest exercise consisting of 30-45 minutes of walking, three times weekly is strongly 
associated with a 50% reduction in the risk of myocardial infarction in women (21).   A regular 
exercise program has also been shown to have a positive impact on other independent risk 
factors such as hypertension, obesity, and diabetes management. 
Obesity, another independent CHD risk factor is associated with diabetes, 
hyperlipidemia, and hypertension.  The risk of CHD increases with increasing weight.  Current 
statistics in the United States identify that 63% of women between the ages of 35-44 years are 
overweight based upon a BMI >25 and 34% of women the same age are obese with a BMI >30 
(19).  Also, previous research has identified that the location of the adiposity stores may increase 
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one’s risk.  Central obesity, quantified as a waist-to-hip ratio greater that 0.8, is associated with a 
disproportionate increase in coronary risk (12). 
The development of Type II Diabetes Mellitus is the most important risk factor for 
coronary disease in women.  Typically, CHD presents at an older age in women than men, 
however, the presence of diabetes mellitus in women wipes out this gender-protective effect.  
Also, in women with diabetes mellitus, coronary disease is more likely to be fatal (8).  
The Adult Treatment Panel (ATP III) has devised guidelines for the treatment of 
hyperlipidemia (63).  The risk factors identified for treatment by the new ATP III guidelines 
include elevated low-density lipoprotein cholesterol (LDL-C), cigarette smoking, hypertension, 
and high-density lipoprotein (HDL-C) less than 40 mg/dL.  The primary therapy recommended 
by ATP III is the lowering of LDL-C regardless of gender by lifestyle management and statin 
drug therapy.  Women with CHD should be treated with therapy focusing on lifestyle changes 
between the ages of 20 to 45 years who have LDL-C levels above 130 mg/dL. The appropriate 
goal recommended is based upon a risk assessment of the individual.  An LDL-C level of less 
than 100 mg/dL is recommended for people with known CHD.  Individuals with two or more 
cardiac risk factors should have an LDL-C < 130 mg/dL.  In the presence of one risk factor the 
goal is to have LDL-C < 160 md/dL.  For asymptomatic women without any risk factors, it is 
recommended that treatment should not be started unless the LDL-C is over 190 mg/dL.   
A secondary therapy recommendation by the ATP III guidelines is identification of the 
“metabolic syndrome”, which is more common in females than males and is characterized by the 
presence of abdominal obesity, dyslipidemia, hypertension, and insulin resistance.  According to 
the ATP III guidelines, a woman would be classified as having metabolic syndrome if they 
exhibited any three or more of the following criteria: 1) waist circumference >88 cm, 2) serum 
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triglycerides > 1.7 mmol/L, 3) blood pressure >130/85 mmHg, 4) HDL cholesterol <1.3 mmol/L, 
and 5) serum glucose >6.1 mmol/L (32).  Since most instances of premature CHD occur in 
women who have a clustering of risk factors as seen in the “metabolic syndrome”, these 
individuals should be targeted for more intensive cardiovascular risk reduction.   
One criticism of the ATP III guidelines is that there is no direct consideration of the 
importance of  HDL-C or triglycerides for the prediction of heart disease in women despite the 
research based evidence that both were shown to be better independent predictors of mortality 
from CHD (9).   Since the lipid profile is not the only factor associated with the etiology of 
CHD, additive tools to help identify cardiovascular risk are needed in women.  According to 
Blake and Ridker (2001), lipid levels and other conventional risk factors explain only 50% of 
coronary events (14).  Ultrasensitive-CRP, a marker of inflammation, should be obtained in 
women who do not closely meet ATP III guidelines but who may still have increased risk for 
CHD (90).    
2.4 The Menopausal Transition 
One determination of menopause can be determined by the woman’s menstrual history 
and can be defined as the absence of menses for 12 consecutive months (16).  It has been 
established that with the onset of menopause the risk of developing CHD increases presumably 
due the estrogen deficiency.  The relative importances of factors which influence the increased 
CHD risk are still unknown.  Substantial components of this increased risk are the lipid 
alterations seen with estrogen deficiency.  Other factors that change with menopause such as 
body fat distribution, insulin action, fibrinolysis, and arterial wall changes may also influence 
cardiovascular risk.  Overall, it is a combination of these factors which contribute to an increased 
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prevalence of metabolic syndrome in postmenopausal women compared with premenopausal 
women (67).   
The distribution of body fat tends to change as a woman enters into menopause with an 
increased central distribution of fat.  Increased intraabdominal fat accumulation has emerged as a 
cardiovascular risk factor independent of overall obesity (40).  Previous research has shown that 
abdominal adiposity increases during the menopause transition independent of the effect of age 
and total body adiposity (69, 108, 13).  Lipid abnormalities are associated with increased 
abdominal adiposity, thus increasing the CHD risk.  High amounts of intraabdominal fat are 
associated with increased insulin resistance, free fatty acid levels, and decreased adoponectin.  
These factors together lead to hypertriglyceridemia and increased hepatic lipase activity which 
further lead to lipid abnormalities.  Overall, compared to premenopausal women, 
postmenopausal women have higher total cholesterol, LDL cholesterol, triglycerides, and 
lipoprotein(a) levels and lower HDL levels (38, 15, 53). 
2.5 Hormone Therapy and Cardiovascular Disease 
Menopause is associated with increased levels of total serum cholesterol, LDL 
cholesterol and triglycerides, as well as a decrease in HDL cholesterol levels which worsen the 
overall cardiovascular risk profile.  It is hypothesized that a major reason for these changes is a 
result of the fluctuation in hormones, especially the deficiency in estrogen.  Thus, the use of 
exogenous hormone therapy could be considered to be justified to improve the cardiovascular 
risk profile.  Generally, estrogen replacement has been shown to decrease total cholesterol, LDL 
cholesterol while increasing HDL cholesterol and triglycerides.  Except for the increased 
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triglyceride levels, these changes are considered positive and may help decrease the overall risk 
for cardiovascular disease. 
Earlier observational studies supported the beneficial relationship between hormone 
therapy use and prevention of CVD (29, 31, 28, 78, 93, 104).  A meta-analysis of 
epidemiological studies suggested that hormone therapy users had an overall 40-50% reduction 
of CVD risk when compared to non-hormone therapy users (30).  However, recent results from 
randomized clinical trials have failed to validate the proposed cardio-protective benefits of 
hormone therapy.   
The secondary prevention randomized clinical trials demonstrate that hormone therapy 
does not slow the progression of coronary disease for women with known heart disease.  The 
Heart and Estrogen/progestin Replacement Study (HERS) is a randomized, double-blind, 
placebo-controlled study which investigated the effect of HRT in secondary prevention of 
cardiovascular disease (36).  This investigation followed 2,763 elderly postmenopausal women 
with documented heart disease for a mean 4.1 years.  The results of this investigation showed no 
significant difference in the overall rates of cardiovascular events between the placebo and HRT 
group.  However, there was a significant increase in cardiovascular events observed during the 
first year of hormone treatment, with a RH of 1.52 (95% CI, 1.01-2.29) suggesting that caution 
be taken when initiating HRT in elderly women with cardiovascular disease (36).    
The Estrogen Replacement and Atherosclerosis trial, a randomized, double-blind, 
placebo-controlled clinical trial, also investigated the effects of HRT on the progression of 
coronary atherosclerosis in women (33).  A sampling of 309 postmenopausal women with 
verified coronary artery disease at baseline were randomized into an estrogen, estrogen plus 
medroxyprogesterone acetate, or placebo group and were followed for three years.  Significant 
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reductions in LDL-cholesterol levels were found in both of the hormone therapy groups as 
compared to placebo.  There was a 9.4% decrease (p=0.02) for the estrogen group, and 16.5% 
(p<0.001) reduction for the estrogen plus medroxyprogesterone acetate group.  Also, significant 
p<0.01 increases in HDL cholesterol levels were observed; 18.8% and 14.2% respectively.  
However, overall there was no significant difference observed in either treatment group on the 
progression of coronary atherosclerosis.   
The results of this investigation were most recently verified by the Women’s Estrogen-
Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial (WELL-HART) (35) and 
The Women’s Angiographic Vitamin and Estrogen (WAVE) trial (100).  Thus, the 
overwhelming evidence suggests that women with existing heart disease should not use estrogen 
replacement with an expectation of cardiovascular benefit.   
In addition to the secondary prevention trials, the primary CVD prevention randomized 
clinical trials also demonstrate that HRT does not prevent cardiovascular events in apparently 
healthy post-menopausal women.  The Women’s Health Initiative (WHI) is a primary CVD 
prevention trial which investigated strategies that could potentially decrease CVD, breast and 
colorectal cancer, and bone fracture risk in postmenopausal women (82).  A very large sample of 
161, 809 post menopausal women aged 50 to 79 years were randomized into one of the study’s 
three separate arms: 1) low-fat dietary pattern, calcium and vitamin D supplementation, 2) 
combined estrogen and progestin hormone therapy, and 3) estrogen only hormone therapy. 
 In the combined estrogen plus progestin hormone therapy arm of the WHI, participants 
(N=16,608) were randomly assigned to receive conjugated equine estrogens (0.625 mg daily) 
plus medroxyprogesterone acetate (2.5 mg daily) or placebo.  The primary outcome was defined 
as acute myocardial infarct (MI) requiring overnight hospitalization, silent MI determined from 
 16 
electrocardiogram, or CHD death.  In 1999, two years after the trial began; the data safety 
monitoring board (DSMB) observed small, early adverse effects in cardiovascular outcomes, 
however none of the disease specific boundaries had been crossed and the trial continued.  In 
2002, the DSMB observed that the adverse effects in cardiovascular diseases persisted and the 
boundary for breast cancer incidence had been crossed.  As a result of the evidence for breast 
cancer harm, and the increase in cardiovascular disease outcomes, the combined estrogen and 
progestin arm was terminated early after a mean follow-up of 5.2 years (planned duration was 
8.5 years) (82).   
The final results with regard to estrogen plus progestin and CHD from the WHI was 
published in 2003 (59).  Overall, the researchers concluded that estrogen plus progestin HRT 
should not be prescribed for the prevention of cardiovascular disease since the therapy had no 
cardio-protective effect and might slightly increase the risk of coronary events.  Compared to the 
placebo group, women taking the combined HRT had a 24% increased risk for CHD with a 
hazard ratio of 1.24 (95% CI, 1.00-1.54).  Subgroup analyses were conducted to determine 
whether any demographic or clinical characteristics put the women at higher risk for CHD.  
Overall, only the subgroup of women with higher baseline LDL cholesterol levels had evidence 
of a pattern of hazard ratios for CHD that were different from patterns found among all women 
(59). 
The estrogen only arm of the WHI investigated the role of 0.625 mg/d of conjugated 
equine estrogen in preventing chronic diseases in 10,739 postmenopausal women with prior 
hysterectomy (6).  As with the estrogen and progestin arm of the WHI, the primary outcome of 
this investigation was defined as acute myocardial infarct (MI) requiring overnight 
hospitalization, silent MI determined from electrocardiogram, or CHD death.  In compliance 
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with the DSMB recommendations, the participants in the estrogen alone trial were informed of 
the early increases in rates of heart disease, strokes, and blood clots observed in the women 
taking hormone pills.  In 2002, the DSMB reported that since no increase in breast cancer rates 
had been observed at that point in the women taking only estrogen, the estrogen only arm of the 
WHI could continue.  The DSMB continued to closely monitor the data and after a review in 
2004, the National Institutes of Health (NIH) decided to stop the intervention phase of the trial.  
The NIH concluded that estrogen therapy did not appear to affect the risk of heart disease, but 
did increase the risk of stroke (6).  Overall, due to the findings of WHI, the current guidelines for 
hormone therapy have changed and routine HRT is not recommended for treatment/prevention of 
chronic conditions including cardiovascular disease.  
Hormone therapy has been shown to impact a number of cardiovascular and metabolic 
risk factors.  The woman randomly assigned to hormone therapy in the estrogen and progestin 
arm of the WHI, had significantly (p<0.05) greater reductions in the total cholesterol, LDL-
cholesterol, glucose and insulin levels as compared with the placebo group (59).  Also, the HRT 
group had significant increases in HDL-cholesterol, and trigylcerides.  There were also 
significant differences in blood pressure.  Systolic blood pressure at year one was 1mmHg higher 
among women receiving hormones than those receiving placebo.  Diastolic blood pressure did 
not differ between groups.  Body weight and waist circumference at follow-up were slightly 
lower among women in the HRT group (59).   
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2.6 Inflammation in Atherogenesis 
There is compelling evidence that inflammation and underlying cellular and molecular 
mechanisms have a role in atherogenesis (54).  Much research has been conducted to determine 
the role of inflammation in atherogenesis.  There is evidence that inflammation aids in the lipid 
accumulation in the artery wall and that inflammatory processes promote the initiation and 
evolution of atheroma, and triggers the thrombus that causes most acute complications of 
atherosclerosis (54).   
Libby, Ridker, and Maseri (2002) concisely outline the impact of inflammation in all 
stages of atherosclerosis.  Blood leukocytes, mediators of host defenses and inflammation, are 
present in the atherosclerotic lesions.  In the early stages of atherosclerosis, an inflammation of 
the endothelial layer of the artery allows blood leukocytes to adhere better than in the normal, 
un-inflamed endothelium.  The leukocytes now adhered to the endothelium, penetrate into the 
intima of the artery.  Within the arterial wall, these cells initiate a local inflammatory response 
that aids in advancing the atherosclerosis lesion.  Ultimately, the intimal lesion is rendered weak 
and becomes susceptible to rupture.  The inflammatory process triggers the potent procoagulant 
tissue factor, which in turn triggers the thrombus that can cause acute myocardial infarction.  
Thus, there seems to be a direct link between arterial inflammation and thrombosis (54).   
Research has also revealed other triggers for inflammation in atherogenesis.  The 
oxidation of lipoproteins such as low-density lipoprotein (LDL) and very low-density lipoprotein 
(VLDL) may also result in inflammation (54).  The oxidation hypothesis states the LDL retained 
in the intima undergoes oxidative modification that causes the newly modified lipids to induce 
the expression of inflammation mediators in macrophages and vascular wall cells (102).  
Similarly, the VLDL molecules can also undergo oxidative modification (54).  Hypertension, a 
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significant risk factor for CHD, also has inflammatory characteristics that may contribute to 
atherosclerosis.  Angiotension II, a vasoconstrictor, has also been linked to increased intimal 
inflammation (43).  Diabetes mellitus is also considered a trigger for inflammation in 
atherogenesis.  Hyperglycemia can lead to modification of macromolecules, which can augment 
inflammatory pathways in vascular endothelial cells (84).  Obesity has multiple roles in 
triggering the inflammation associated with atherogenesis.  Not only does obesity increase the 
risk of insulin resistance and diabetes, but it also contributes to dyslipidemia; all which may 
cause inflammation (54).  Obesity directly increases inflammation due to adipose tissue 
synthesizing proinflammatory cytokines such as interleukin-6, a primary hepatic stimulant for 
CRP production (107).  Lastly, chronic infection may increase inflammatory cytokines that may 
accelerate the evolution of remote atherosclerotic lesions (22).   
2.7 CRP and Cardiovascular Risk Prediction 
Currently, there is compiling evidence that using inflammatory markers such as CRP in 
coronary risk prediction may increase the accuracy in detecting patients at high risk for 
subsequent coronary occlusion.  C-reactive protein is an acute phase reactant, which is a marker 
for underlying systemic inflammation.  Several large prospective studies of apparently healthy 
adults have shown an association between elevated CRP levels and the risk of coronary events 
(48, 75, 76, 79), stroke (83), and peripheral vascular disease (74), independent of traditional risk 
factors.  Thus, CRP testing conducted during primary prevention in combination with lipid 
screening may improve the global assessment of cardiovascular risk (73).   
 A strong association between CRP and cardiovascular risk has been shown in men.  
However, the relation of CRP and cardiovascular risk in women is not well established.  C-
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reactive protein and other inflammatory markers were collected in a cohort of apparently healthy 
post-menopausal women participating in the Women’s Health Study (76).  Twelve 
measurements including four inflammatory markers and eight lipid parameters were collected at 
baseline and study participants were followed for a mean of three years.  For each woman who 
had a confirmed cardiovascular event during follow-up, two control subjects were matched for 
both age and smoking status.  Overall, 122 case subjects and 244 control subjects were selected 
for analysis.  C-reactive protein and the other markers of inflammation were significantly 
elevated at baseline in those women who subsequently developed a cardiovascular event.  Also 
observed in the post-event cases, was a significant elevation in total cholesterol, LDL 
cholesterol, and the ratio of total to HDL cholesterol.   
Interestingly, the researchers found that of the twelve markers measured, CRP was the 
strongest univariate predictor of risk with an odds ratio of 4.4 for the highest quartile compared 
with the lowest quartile; 95% CI [2.2-8.9], p<0.001 (76).  After adjusting the risk model for 
BMI, hypertension, diabetes, and parental history of premature CHD, CRP (p<0.02) and the ratio 
of total cholesterol to HDL cholesterol (p<0.02) were found to be independent risk predictors.  
The researchers concluded that the addition of inflammation markers to classic lipid testing 
clinically provided a significantly better risk prediction model than just lipid testing alone 
(p<0.001).  Clinically, the most interesting finding was involving the sub-grouping of women 
with “safe” levels of LDL cholesterol, classified by NCEP as <130 dL.  In this investigation, 
women within this LDL-group who had elevated baseline levels of CRP and the other 
inflammatory markers were also found to be at increased risk for future cardiovascular events.  
The relative risk of 4.1 was observed for women in the highest quartile as compared to the lowest 
quartiles; 95% CI [1.7-11.3], p<0.002.   
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This study provides some important clinical implications.  First, the addition of screening 
for CRP in primary prevention may better identify patients who would benefit from moderate 
risk reduction.  Secondly, it is important to recognize that a lipid profile within established 
“goal” guidelines may not be enough to protect from CHD.  There remains a need for a 
comprehensive risk prediction model that includes lipid parameters, markers of inflammation, 
and other lifestyle risk factors.  
Similar results were reported by the research team led by Ridker, 2002 utilizing a much 
larger cohort of the Women’s Health Study (77).  Baseline CRP and LDL cholesterol levels were 
obtained and the women were followed for a mean of eight years.  With the large sample size of 
27,939 women, the researchers were able to calculate survival curves associated with CRP and to 
compare the relationship between CRP and LDL cholesterol to predict coronary events.  Also, 
due to the large sample, the researchers were able to separately examine those women who were 
nonusers and users of hormone-replacement therapy.  
The results of this study showed that both baseline values of CRP and LDL cholesterol 
had a strong linear relationship with the incidence of coronary events.  However, CRP and LDL 
were minimally correlated (r=0.08) to each other.  The relative risk of first cardiovascular events 
according to increasing quintiles of CRP were 1.4, 1.6, 2.0, and 2.3, as compared to those in the 
lowest quintile (p<0.001) and according to LDL cholesterol were 0.9, 1.1, 1.3, and 1.5, 
respectfully (p<0.001).  Thus, the researchers concluded that CRP was a stronger predictor than 
LDL cholesterol for cardiovascular events.   
Similarly to the study conducted by Ridker in 2000, an overwhelming amount of 
cardiovascular events occurred in women at “goal” levels of LDL cholesterol.  In this large 
sample, 77% of the coronary events occurred in women with LDL levels below 160 dL and 46% 
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occurred in women whose LDL was below 130 dL (77).  The results of this larger study again 
illustrate the need for CRP levels to be considered with the entire lipid panel for better overall 
risk stratification.  
Based upon the recommendations from the previous mentioned studies, a cross-sectional 
survey was conducted comparing CRP levels with calculated 10-year Framingham Coronary 
Heart Disease Risk Scores (FCRS) of 1666 men and women free of cardiovascular disease (4).  
The researchers found that CRP levels significantly correlated with the 10-year FCRS in women 
not taking hormone replacement therapy and men.  The data showed a positive trend between 
increasing CRP levels and progressively higher FCRS with the use of the total cholesterol (ptrend< 
0.01) and LDL cholesterol (ptrend<0.01) scoring algorithms.  However, when CRP was correlated 
with each individual component of the FCRS, no significant correlation was observed.  Overall, 
the results of this investigation support the hypothesis that CRP and the FCRS may reflect 
different aspects of coronary risk; therefore the addition of CRP in the overall risk determination 
may be useful.  
2.8 Physical Activity Assessment 
Among the body of research investigating cardiovascular health, physical activity 
patterns and cardiorespiratory fitness levels are critically important.  Physical activity can be 
defined as voluntary movement produced by skeletal muscles which results in energy 
expenditure (17).  The term physical activity includes a vast spectrum of activities; at the lower 
end are general activities of daily living and at the other end are moderate to high intensity 
activities (44).  Therefore, housework, gardening, occupational, and leisure activity may all be 
considered types of physical activity.  The term exercise differs from physical activity in that it is 
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planned, structured, and consists of repetitive movements with the purpose to improve or to 
maintain one or more components of physical fitness (17).  Physical fitness is defined as an 
overall set of attributes including cardiorespiratory fitness and muscular strength, that an 
individual possesses or can achieve that relates to the ability to participate in exercise or physical 
activity (17).   
The overall definition of physical activity is broad and allows for much interpretation; 
therefore clouding the ability to compare methods of assessment.  Therefore, it is imperative to 
select a subjective measurement tool such as the questionnaire carefully so that it captures the 
information on the types of physical activities that encompass the greatest proportion of energy 
expenditure in the study population (44).  To accurately assess physical activity levels, the 
assessment tool should capture the entire spectrum of activity.       
According to a meta-analysis conducted by Williams, 2001, there is a wide array of 
research investigations which have looked at self-reported physical activity and cardiovascular 
disease (101).  However, among these epidemiological studies, the method of collecting 
information on physical activity has varied widely making interstudy comparisons almost 
impossible.  The physical activity questionnaires used differ by recall period, type of activity 
recorded, and whether the physical activity is ranked by total expenditure or intensity (101).     
Physical activity can be assessed using either subjective or objective measures.  Self-
reported questionnaires are widely used to subjectively assess physical activity.  Questionnaires 
can vary in their complexity, time frame, and activity type (68).  The questionnaire may ask a 
single item, or be comprised of a more complex history.  They may require the respondent to 
recall activity within the past day, week, month, or even over a lifetime.  The questionnaires 
which recall activity done over a long time frame, such as 1 year, are more likely to reflect the 
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usual activity patterns of the individual.  Comparatively, the questionnaires with a short time 
frame are less likely to be vulnerable to recall bias and the physical activity measured is more 
easily validated with objective tools.  Lastly, the physical activity type measured may include 
domains such as school/occupational, sports/leisure, or housework/child or elderly care.   
A popular objective measurement tool of physical activity is the pedometer.  Pedometers 
are small, inexpensive devices that measure ambulatory activity in terms of steps taken (11).  
Each step is registered when the vertical forces of foot-strike cause movement of a spring-
suspended lever arm.  Pedometers have been shown to be a reliable tool when walking is the 
primary type of activity (10).  Pedometers do have some limitations.  First, any vertical force 
through the hip area can trigger the device.  Therefore, the pedometer may falsely capture 
movement not associated with physical activity.  Secondly, pedometers do not provide 
researchers with information relating to activity type, duration, or intensity.  Lastly, pedometers 
do not capture activity done with the upper body alone and have been shown to not be accurate 
when the gait speed is slow (11).     
2.9 Physical Activity and Postmenopausal Women 
Physical activity has been shown to be a negative risk factor for CHD in women.  
Evidence from previous research shows that individuals who participate in regular physical 
activity have a reduced risk of developing CHD (86, 96).  However, more than 41% of 
postmenopausal women are physically inactive during their leisure time (88).   
Many prospective studies investigating physical activity and cardiovascular disease in 
postmenopausal women have found an inverse relationship (49, 60, 59, 52).  Both moderate and 
vigorous physical activity has been associated with substantial reductions in the incidence of 
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cardiovascular events.  In these investigations, physical activity was assessed using varying 
subjective questionnaires which makes interstudy comparison more difficult.  Overall, based 
upon the evidence, low to high levels of physical activity has been shown to reduce 
cardiovascular risk in this population of women.  
2.10 Physical Activity and CRP 
Research investigations have shown inverse associations between physical activity levels 
and CRP in an apparently healthy adult population (25, 5).  However, other research 
investigations suggest that the relationship between CRP and physical activity is not as strong as 
the impact of body mass index and/or body fat is on CRP levels (71, 98).  Lastly, the association 
between physical activity and CRP in postmenopausal women has not been widely studied (95, 
57). 
An investigation conducted by Ford, 2002 explored the association between CRP and 
physical activity in a large (N=13,748) representative sample of the U.S. population (25).  This 
sample included individuals who participated in the National Health and Nutrition Examination 
Survey III (NHANES III).  The results of this investigation support the hypothesis that physical 
activity may reduce inflammation (25).  The researchers found that the amount of leisure-time 
physical activity was inversely associated with baseline serum CRP levels (p<0.001).  Even after 
adjustments were made for confounding variables including BMI and waist-hip ratio, a 
significant relationship between physical activity and CRP remained.    
The inverse association between physical activity and CRP was verified in an 
investigation conducted by Albert, 2004 (5).  The sample included 1,732 men and 1,101 women 
who participated in the Pravastatin Inflammation/CRP Evaluation (PRINCE) study.  The inverse 
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relationship between self-reported physical activity and CRP after adjustment for confounders 
was only apparent for the men (p=0.007) and not for the women (p=0.38).  The investigators 
hypothesized that this gender difference may be an effect of the subject size and also due to the 
women reporting lower amounts of physical activity.   
Two other recent investigations failed to confirm this inverse relationship between 
physical activity and CRP (71, 98).  In both of these investigations, BMI not physical activity 
was significantly related to CRP levels.  The absence of an affect of physical activity on CRP in 
these two investigations could be due to smaller sample sizes and also a large proportion of the 
samples being sedentary.   
The relationship between CRP and physical activity in postmenopausal women has also 
been investigated (95, 57).  Findings from these studies suggest that physically active 
postmenopausal women had lower CRP levels, regardless of hormone therapy status, when 
compared to their less active counterparts.  Manns et al., (2003) designed a study to determine if 
increased participation in physical activity was associated with a reduction in CRP levels 
independent of hormone therapy and body fat in postmenopausal women.  One hundred thirty-
three women between the ages of 50 and 78 were included in the study sample.  Fifty of the 133 
women were not hormone therapy users, 51 took estrogen plus progestin, and the remaining 32 
used estrogen only.  Physical activity was assessed using a Stanford 7 Day Physical Activity 
Recall.  The median CRP levels for women on hormone therapy (with or without progestin) was 
3.5 – 5.5 times higher than those not taking hormone therapy (median CRP level was highest 
among those women taking unopposed estrogen).  Increased participation in physical activity 
reduced CRP levels regardless of hormone therapy use.  However, as hypothesized, this 
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association was dependent upon lower amounts of body fat that were observed in the active 
women (57).   
Investigators also examined the hypothesis that hormone replacement therapy related 
increases in CRP would either be blunted or absent in those postmenopausal women who 
regularly exercised (95).  The sample studied (N=114) included 39 physically active and 75 
sedentary postmenopausal women.  Sixty-five women were users of hormone therapy and 49 
were nonusers.  Plasma CRP levels were ~75% higher (p<0.01) in the sedentary group who were 
hormone therapy users when compared to sedentary non-users.  There was no significant 
difference in CRP levels between hormone therapy groups for the physically active women.  
Additionally, plasma CRP levels in the physically active hormone therapy users and non-users 
were 68% and 64% lower than their sedentary counterparts.  The researchers concluded that 
since the elevation in CRP due to hormone replacement therapy observed in sedentary women is 
absent in women who engage in regular physical activity, physical activity may prevent the 
increase in CRP due to hormone replacement therapy (95).   
2.11 Cardiorespiratory Fitness and CRP 
Only a few studies have examined the association of cardiorespiratory fitness and CRP 
(20, 51).  Church et al. (2002) assessed cardiorespiratory fitness with a maximal treadmill test 
and examined the prevalence of elevated CRP values in a sample of 722 men from the Aerobics 
Center Longitudinal Study (20).  The subjects were also screened for many cardiovascular 
disease risk factors including body mass index, blood pressure, fasting glucose, and lipid levels.  
Each variable was analyzed by CRP quartiles and by fitness quintiles.  There was a statically 
significant positive association between CRP levels and BMI (p<0.0001), systolic blood pressure 
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(p<0.0001), diastolic blood pressure (p<0.0001), fasting glucose (p= 0.001), and triglycerides 
(p<0.0001).  Also, a significant inverse relationship was observed between CRP and fitness 
(p<0.0001), and HDL cholesterol (p<0.0001).   
The secondary analysis revealed that CRP levels were significantly different across 
fitness quintiles (p<0.001).  Subjects within the lower fitness group had higher CRP values than 
those in the higher fitness quintile.  This association was independent of body composition and 
fat distribution, as assessed by BMI, percent body fat, and waist girth.  The authors suggest that 
since there remained a strong association between fitness and CRP concentration after 
accounting for the possible confounding factor of BMI, individuals may be able to decrease CRP 
levels by increasing fitness even without substantial weight loss (20).   
This association between cardiorespiratory fitness and CRP levels was also examined in a 
sampling of apparently healthy (44 African Americans, 45 Native Americans, and 46 Caucasian) 
women (51).   A maximal treadmill exercise test was administered to determine cardiorespiratory 
fitness.  Other variables collected included: BMI, resting blood pressure, fasting insulin and 
glucose, lipid profile, apolipoprotein B, and homocysteine.  The researchers analyzed CRP 
concentrations across categories of race, fitness, and BMI.   
Overall, among the entire cohort, CRP correlated significantly with fitness (r= -0.25), 
BMI (r= 0.25), waist girth (r= 0.21), insulin (r= 0.26), and triglyceride (r= 0.27).  The authors 
also reported significant correlations between CRP and race (p=0.002), fitness (p=0.002), BMI 
(p=0.0007), and waist girth (p=0.004).  C-reactive protein levels were lowest among the 
Caucasian women and highest among the African American women.  An inverse relationship 
was observed between CRP and fitness.  Linear, positive trends existed across BMI and waist 
girth.  This investigation of women provided similar results as the Church, 2002 investigation of 
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men.  Although there is limited research investigating CRP and cardiorespiratory fitness, 
preliminary evidence suggests that exercise training which increases cardiorespiratory fitness 
may reduce CRP levels and therefore CHD risk.     
2.12 Subclinical Measurements 
Electron beam computerized tomography (EBCT) is a non-invasive scanning technique 
that allows both detection and quantification of coronary artery calcium.  This test may be 
beneficial in the early diagnosis of CHD since more coronary calcium means more coronary 
atherosclerosis, suggesting a greater likelihood of future cardiovascular problems.  Under the 
assumption that calcification precedes manifestation of coronary artery disease, this radiologic 
appearance of calcium may be used to assess CHD risk.   
Briefly, the EBCT technique involves taking 30 to 40 axial images of the myocardium.  
The tomographic slices have a fixed slice thickness of 3 mm, and the entire coronary tree is 
imaged during a single 20-30 second breath hold.  The rapid acquisition at 100 msec allows 
accurate visualization of calcium deposits in the coronary tree.  Since calcium attenuates the x-
ray beam, computed tomography is extremely sensitive in detecting vascular calcification (26).  
The coronary calcium score is most often calculated using the Agatston scoring method: the 
calcium area (square millimeters) is multiplied by a modifier that adjusts for peak calcium 
density for each lesion (2).  Several commercial software packages have incorporated this 
scoring protocol and are used to quantify the coronary arterial calcification.  
Coronary calcium scores have been found to be predictive of CHD in women (42, 89, 
70).  Outcome data was collected from a large cohort (N=5635) of asymptomatic males and 
females (36%) for a mean of 37 + 13 months (42).  At baseline, EBCT images were taken and 
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coronary calcium scores were calculated.  During follow-up, a variety of endpoints including 
cardiovascular mortality, myocardial infarction, and revascularization procedures were recorded.  
Overall, 51% of the women had visible coronary artery calcium at baseline.  In women, the 
occurrence of all events was significantly associated with the presence of coronary artery 
calcium (p=0.037).  The findings of Kondos et al, 2003 was verified by the results of a 
longitudinal investigation which followed a large cohort (N=10,377) of asymptomatic men and 
women (40%) for an average of 5 + 3.5 years (89).  In both genders, coronary artery calcium was 
an independent predictor of death (p<0.001) and the risk increased proportionally to the baseline 
calcium scores by EBCT.      
Coronary calcification as measured by EBCT has been shown to be associated with 
traditional risk factors of coronary artery disease in women.  The Healthy Women Study (HWS) 
investigated the relationship between cardiovascular risk factors measured premenopausally and 
coronary calcification measured 11 years later (47).  At the follow-up visit, 63% of the women 
had no calcification in the coronary arteries as measured by EBCT.  The investigators did find 
relationships between conventional risk factors and coronary calcification scores.  There were 
very strong associations between coronary calcification and LDL cholesterol (p=0.0001), HDL 
cholesterol (p= 0.0001), and HDL2 cholesterol (p=0.0000).  The women with an LDL-C <100 
mg/dL had no calcification.  Also, women with a lower HDL-C had a much higher prevalence of 
coronary calcification.  Other risk factors found to be significantly related to coronary calcium 
scores were: systolic blood pressure, 2-hour blood glucose levels, trigylcerides, apoB, BMI, and 
cigarette smoking.  This was the first study to examine the relationship of risk factors measured 
premenopausally to the extent of subclinical disease by EBCT among postmenopausal women.   
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 The association of traditional and nontraditional cardiovascular risk factors with 
coronary artery calcification was further examined in a cohort of the Atherosclerosis Risk in 
Communities (ARIC) Study (24).  Coronary artery calcium was measured by EBCT in 360 
individuals free of known coronary artery disease.  The coronary calcium scores were related to 
other risk factors measured approximately 12 years prior.  Most of the traditional risk factors 
were associated with the coronary calcium score after adjustment for age and gender.  Coronary 
calcium scores were associated positively (p<0.05) with total and LDL-cholesterol, triglycerides, 
waist/hip ratio, pack/years of smoking, diabetes prevalence, and hypertension.  There also was a 
significant negative association with HDL-cholesterol.  Interestingly, the researchers did not find 
significant associations between the coronary calcium score and sports physical activity, insulin, 
nor with the inflammation marker CRP.  In this investigation, only the traditional cardiovascular 
risk factors were associated with coronary calcification and no evidence was found for the 
inclusion of the “non-traditional” risk factors in the overall CHD risk assessment model.     
The relationship between CRP and coronary calcification has yet to be strongly 
determined.  Some previous research investigations have shown a correlation (99, 65) while 
others have not found any relationship (72, 37) between the marker of inflammation and 
coronary calcification.  Most recently, the St. Francis Heart Study compared the prognostic 
accuracy of EBCT scanning of the coronary arteries with that of coronary disease risk factors 
and CRP (7).  A large sample of 4,903 asymptomatic men and women were observed over a 
period of 4.3 years.    This investigation added to the literature supporting the prognostic value of 
coronary calcification to atherosclerotic cardiovascular disease events.  Those subjects which had 
an event, had statistically higher baseline coronary calcium scores than those without events 
(p<0.0001).  The results of this investigation also yielded an association between most standard 
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risk factors with CRP and the coronary calcium score.  The coronary calcium score and CRP 
together were weakly correlated (r=0.06, p=0.01).  However, in a multivariate regression model 
after adjustment for standard risk factors, CRP levels no longer predicted the coronary calcium 
score (p=0.22).  Lastly, the researchers found that the calcium score predicted coronary artery 
disease events more accurately than the Framingham risk index (p=0.0006).  In combination with 
the Framingham risk score, the addition of the calcium score enhanced overall risk stratification 
(p<0.0001).  Therefore, it was concluded that the coronary calcium score may enhance risk 
stratification by identifying individuals with greater risk who were originally classified as low-
risk.   
The relation of physical activity to the coronary artery calcium score has also been 
examined (23).  A cross-sectional investigation of 779 asymptomatic men and women who had 
multiple metabolic risk factors was conducted with the primary purpose of examining whether an 
increasing degree of physical activity would be inversely associated to the prevalence of 
coronary artery calcium.  Study participants were categorized into 3 groups based upon their past 
year leisure time physical activity: sedentary (no PA), moderate-duration PA (<30minutes, 1-2 
times/week), and long-duration PA ( >30 minutes, >3 times/week).  Overall, 37% of the 
participants were sedentary, 26% engaged in moderate-duration, and 37% in long-duration.  A 
relationship between physical activity and coronary calcification was apparent in this 
investigation.  Advanced coronary artery calcium was prevalent in 26% of the sedentary group, 
24% of the moderate-duration group, and 16% of the individuals in the long-duration group 
(p<0.05).  Thus, long-duration physical activity had an independent inverse association with 
coronary artery calcium. 
 33 
2.13 Summary 
Cardiovascular disease is the leading cause of death and an important contributor to 
morbidity and disability among women.  This disease is largely preventable, and epidemiological 
research suggests that aggressive risk reduction including counseling about lifestyle should be an 
ongoing process throughout a women’s life.   Frighteningly, according to the AHA (2002), 63% 
of women who died suddenly from CVD had no previous symptoms.  Thus, individual 
awareness of symptomology, family history, and early cardiovascular screening is important to 
identify this disease early.   
Conventional risk factors for CHD in women are well documented and include obesity, 
smoking, physical inactivity, dyslipidemia, hypertension, and diabetes mellitus.  Commonly 
identified in women is metabolic syndrome which is characterized by the presence of abdominal 
obesity, dyslipidemia, hypertension, and insulin resistance.  Since most instances of premature 
CHD occur in women who have a clustering of risk factors, these individuals should be targeted 
for more intensive cardiovascular risk reduction.  Unfortunately, lipid levels and other 
conventional risk factors explain only 50% of coronary events.  Therefore, it has been suggested 
that ultrasensitive CRP, a marker of inflammation, should be obtained in women who may have 
increased CHD risk but a normal lipid profile.   
The onset of menopause increases the risk of developing CHD presumably due the 
estrogen deficiency.  The relative importances of factors which influence the increased CHD risk 
are still unknown.  Substantial components of this increased risk are the lipid alterations seen 
with estrogen deficiency.  Other factors that change with menopause such as body fat 
distribution, insulin action, fibrinolysis, and arterial wall changes may also influence 
cardiovascular risk.  Earlier observational studies supported the beneficial relationship between 
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hormone therapy use and prevention of CVD.  A meta-analysis of epidemiological studies 
suggested that hormone therapy users had an overall 40-50% reduction of CVD risk when 
compared to non-hormone therapy users.  However, recent results from randomized clinical trials 
have failed to validate the proposed cardio-protective benefits of hormone therapy.   
There is evidence that inflammation aids in the lipid accumulation in the artery wall.  In 
addition, these inflammatory processes promote the initiation and evolution of atheroma, and 
trigger the thrombus that causes most acute complications of atherosclerosis.  Within primary 
prevention, utilizing inflammatory markers such as CRP in coronary risk prediction may increase 
the accuracy in detecting high-risk patients for subsequent coronary occlusion.  Previous 
research demonstrates a positive linear association between CRP and cardiovascular risk in men 
while studies investigating women are less numerous.  There is compelling evidence that a 
comprehensive risk prediction model that includes lipid parameters, markers of inflammation, 
and other lifestyle risk factors together may provide the best CHD risk screening outcome. 
Both moderate and vigorous physical activity has been associated with substantial 
reductions in the incidence of cardiovascular events in postmenopausal women.  Inverse 
associations between physical activity levels and CRP have been observed in apparently healthy 
adult populations.  However, other research investigations suggest that the relationship between 
CRP and physical activity is not as strong as the impact of body mass index and/or body fat is on 
CRP levels.  Lastly, the association between physical activity and CRP in postmenopausal 
women has not been widely studied. 
Electron beam computerized tomography (EBCT) is a non-invasive scanning technique 
that allows both detection and quantification of coronary artery calcium.  Coronary calcification 
as measured by EBCT has been shown to be associated with traditional risk factors of coronary 
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artery disease in women.  The relationship between CRP and coronary calcification has yet to be 
strongly determined.  
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3.0  PROCEDURES 
3.1 Introduction 
The primary purpose of this study was to examine the associations between C-reactive 
protein (CRP) and physical activity on the risk factor profile of postmenopausal women without 
known heart disease who were either taking or not taking hormone therapy.  The secondary 
purpose of this investigation was to examine the relation of other cardiovascular risk factors on 
subclinical measures of coronary heart disease (CHD).  This chapter is separated into the 
following sections: (1) Selection of Subjects, (2) Collection of Data, (3) Treatment of Data, and 
(4) Summary. 
3.2 Selection of Subjects 
A cohort of 201 postmenopausal, 52-62 year old women who are enrolled in the Women 
On the Move through Activity and Nutrition (WOMAN) Study was examined at the baseline 
evaluation.  The WOMAN study is a 5-year randomized clinical trial of primary cardiovascular 
disease prevention in Pittsburgh, Pennsylvania.  The primary purpose of this study is to test 
whether an aggressive non-pharmacological intervention among postmenopausal women will 
modify or reduce measures of subclinical cardiovascular disease.  Currently, this longitudinal 
study is collecting the 30 and 42-month data.  The women were recruited in the community 
through mailings, and contacts with physician offices in the Pittsburgh area.  Initially, to be 
eligible for participation, the subjects had to be currently taking hormone replacement therapy 
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(HRT).  However, due to the publication of the negative effects of HRT in the Women’s Health 
Initiative (WHI), the eligibility criteria changed and women who were not HRT users were 
eligible to participate as well.  Therefore, there are currently women taking HRT and those not 
taking HRT in the study.   
Other inclusion criteria for enrollment into the WOMAN study included a waist 
circumference >80 centimeters, a LDL cholesterol level between 100-160 mg/dL, and the 
physical ability to participate in a walking intervention.  Individuals were excluded based upon 
self-report if they had known heart disease, or diabetes mellitus, were currently on lipid lowering 
drug therapy, or were being treated for major psychiatric disorders or depression.  All subjects 
signed an approved informed consent form prior to data collection.  The WOMAN study 
research protocol was approved by the University of Pittsburgh’s Institutional Review Board 
(IRB# 000356).  The secondary analysis of the WOMAN study for the purpose of this 
dissertation project was also approved (IRB# 0602160). 
Table 1: Baseline Visit WOMAN Study Measurements 
Completed Clinic Visit  
(demographic survey, medication inventory, 
anthropometric measures, blood pressure, and 
fasting blood draw) 
 
n=508 
Physical Activity Measures 
            Past Year MAQ 
            Past Week MAQ 
            Pedometer 
 
 
n=504 
 
n=506 
 
n=173 
Cardiovascular Disease Risk Factors 
           hs-CRP 
 
n=201 
Subclinical Measures of CHD 
           Coronary Artery Calcification 
           Carotid Ultrasound            
 
n=507 
n=503 
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3.3 Collection of Data 
Data was collected in the University of Pittsburgh’s Department of Epidemiology 
Research Center located in Pittsburgh, PA by trained researchers.  All clinical procedures used 
standardized protocols and calibrated equipment.  The baseline data collection form can be 
located in Appendix A. 
3.3.1 Phlebotomy 
Blood samples were obtained after a 12 hour fast by venipuncture of an antecubital vein 
by a trained phlebotomist for analysis of total cholesterol, HDL cholesterol, LDL cholesterol, 
triglycerides, fasting glucose and insulin, and high sensitivity CRP.  Analysis of glucose, insulin, 
and lipid profile was done in the Heinz Nutrition Laboratory in the Department of Epidemiology 
at the Graduate School of Public Health, University of Pittsburgh.   
High sensitivity CRP was analyzed in the Lab for Clinical Chemical Research at the 
University of Vermont.  C-reactive protein was measured using the BNII nephelometer from 
Dade Behring utilizing a particle enhanced immunonepholometric assay.  Polystyrene particles 
are coated with monoclonal antibodies to CRP, which, in the presence of antigen (CRP) 
agglutinate to cause an increase in the intensity of scattered light.  The increase in scattered light 
is proportional to the amount of CRP in the sample.  Suitable specimens for this assay are serum, 
heparin, or EDTA anticoagulated plasma.  The assay range is 0.175 – 1100 mg/L. Expected 
values for CRP in normal, healthy individuals are < 3 mg/L.  Intra-assay CVs range from 2.3 – 
4.4% and inter-assay CVs range from 2.1 – 5.7%.  The phlebotomy collection form used in the 
WOMAN study can be found in Appendix B. 
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3.3.2 Subject Characteristics 
Subject characteristics including body weight, height, body mass index (BMI), and waist 
circumference were recorded.  Body mass index was calculated from weight divided by height2 
(kg*m-2).  Waist circumference was measured at the level of the umbilicus and recorded in 
centimeters. 
3.3.3 Subclinical Disease Measures 
Electron Beam Computed Tomography (EBCT) was used to quantify calcification in the 
coronary arteries.  An Imatron C-150 Ultrafast CT Scanner (Imatron, South San Francisco, CA) 
was used to perform two passes.  The first is a scout pass that allows an evaluation of the 
subject’s anatomy so that the landmarks for the coronary scan can be identified.  The second pass 
is for evaluation of the coronary arteries.  During this pass, 30 to 40 contiguous 3mm thick 
transverse images were obtained from the level of the aortic root to apex of the heart.  Images 
were obtained during a maximal breath hold using ECG triggering so that each 100 millisecond 
exposure is obtained during the same phase of the cardiac cycle (60% of R-R interval).  A 
DICOM work station and software by AcuImage was used to read the images.  This software 
program implements the widely accepted Agatston scoring method.  Coronary artery calcium 
will be considered to be present when 3 contiguous pixels greater than 130 HU are detected 
overlying the vessels of interest.  A total calcium score as well as a total number of calcifications 
was obtained.   
A carotid ultrasound was conducted to obtain average wall (intima-media) thickness 
measurements.  A Toshiba SSA-270A scanner was used to take detailed B-mode images of the 
right and left common carotid artery, carotid bifurcation, and the first centimeter of the internal 
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carotid.  Selected images were digitized for later measurement of intima-media thickness by 
central readers in Pittsburgh.     
3.3.4 Physical Activity Assessment 
To assess current physical activity behaviors, an interviewer administered the Modifiable 
Activity Questionnaire (MAQ), Appendix C, which assesses occupational and leisure activities 
done in the past year (45).  The subject’s average past year physical activity was calculated as the 
product of the duration and frequency of each activity (hours/week).  Each activity then can be 
weighted by their estimated metabolic cost (METs) and ultimately expressed as MET-hours per 
week.  A summation of each activity will give a total average past year physical activity score in 
either hours/week, or MET-hours.  The MAQ has been shown to be both reliable and valid in 
adults through comparisons with activity monitors and doubly labeled water (46, 85).    
A past week version of the MAQ was also used to assess participation in leisure activities 
performed over the past 7 days.  Study participants were given the past week MAQ during the 
eligibility visit and were asked to record leisure activities for the 7 days prior to their clinic 
assessment.  Past week leisure physical activity levels were calculated using the same methods as 
the past year MAQ. 
Physical activity was also objectively measured in some subjects using the Yamax Digi-
Walker pedometer.  The pedometer was worn clipped to the waistband over the dominant hip for 
one week.  At the end of each day, the subject was asked to record the total number of steps 
taken in a dairy which was then returned to the investigator (Appendix C).  For each participant, 
a seven-day average of the number of the steps taken per day was calculated.   
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3.4 Treatment of Data 
Data analysis was done using SAS Software (SAS Institute Inc., NC).  All variables were 
tested for normality.  Normally distributed variables were reported as mean + standard deviation; 
not normally distributed variables were reported as median with 25th and 75th percentiles.  
Depending upon the characteristics of the variables, Pearson or Spearman correlation coefficients 
were utilized to examine associations between continuous variables.  Chi Square models were 
used to examine relationships between categorical variables.  Multiple linear multiple regression 
models with CRP value as the dependent variable and with physical activity, HRT status, waist 
circumference, age, smoking status, total cholesterol, HDL-c, triglycerides, glucose, CACS, and 
carotid artery intimal thickness as the independent variables were used to identify the factors that 
are related to CRP.  A logistic stepwise regression model with detectable coronary artery calcium 
(0-10, >10) as the dependent variable and with CRP, physical activity, carotid artery intimal 
thickness, total cholesterol, HDL-c, triglycerides, waist circumference, HRT status, and age as 
the independent variables was used to determine the factors that are related to the CACS.  
Independent t-tests and Wilcoxon rank scores were used to determine if there were differences in 
CRP, CACS, intimal thickness, physical activity and other cardiovascular risk factors among 
those women with and without characteristics of metabolic syndrome.  All statistical testing was 
conducted at the p<0.05 level of significance.  
3.5 Summary 
A cohort of 201 postmenopausal, 52-62 year old women who are enrolled in the Women 
On the Move through Activity and Nutrition (WOMAN) Study was examined at the baseline 
evaluation which occurred 30-42 months ago.  Inclusion criteria for enrollment into the 
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WOMAN study included a waist circumference >80 centimeters, a LDL cholesterol level 
between 100-160 mg/dL, and the physical ability to participate in a walking intervention.  
Individuals were excluded if they had known heart disease, or diabetes mellitus, were currently 
on lipid lowering drug therapy, or were being treated for major psychiatric disorders or 
depression.  All subjects signed an approved informed consent form prior to data collection.  The 
WOMAN study research protocol was approved by the University of Pittsburgh’s Institutional 
Review Board (IRB# 000356).  The secondary analysis of the WOMAN study for the purpose of 
this dissertation project was also approved (IRB# 0602160). 
Fasting blood samples were collected by venipuncture of an antecubital vein by a trained 
phlebotomist at the University of Pittsburgh’s Department of Epidemiology Research Center 
located in Pittsburgh, PA for analysis of total cholesterol, HDL cholesterol, LDL cholesterol, 
triglycerides, fasting glucose and insulin, and high sensitivity CRP.  Body weight and height 
were measured and BMI was calculated.     
Subclinical disease measures were also obtained.  Electron Beam Computed Tomography 
(EBCT) was used to quantify calcification in the coronary arteries.  Coronary artery calcium was 
considered to be present when 3 contiguous pixels greater than 130 HU are detected overlying 
the vessels of interest.  A total calcium score using the Agatston scoring method as well as a total 
number of calcifications was obtained.  A carotid ultrasound was conducted to obtain average 
wall (intima-media) thickness measurements.  Selected images were digitized for later 
measurement of intima-media thickness by central readers in Pittsburgh.     
Lastly, the subjects completed the MAQ which assessed occupational and leisure 
activities done in the past year.  The subject’s average past year physical activity score can be 
expressed in either hours/week, or MET-hours.  Data was analyzed using SAS.  All statistical 
testing was conducted at the p< 0.05 level of significance.   
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4.0  RESULTS 
4.1 Introduction 
The primary purpose of this study was to examine the associations between C-reactive 
protein (CRP) and physical activity on the risk factor profile of postmenopausal women without 
known heart disease who were either taking or not taking hormone therapy.  The secondary 
purpose of this investigation was to examine the relation of other cardiovascular risk factors on 
subclinical measures of coronary heart disease (CHD).   
4.2 Subject Characteristics 
A cohort of participants from the WOMAN study (n=508) was used for this investigation 
of baseline data.  The 201 women included in this cohort had CRP blood analysis drawn at 
baseline thus meeting eligibility requirements.  All of the women were postmenopausal with a 
mean age of 57.14 (+ 2.92) years with 160 (80%) taking HRT and 41 (20%) not on HRT.  The 
majority of the sample was Caucasian (93%).  Table 2 identifies further information regarding 
the characteristics of the sample.  Baseline measurements taken from the cohort were tested for 
normality and are reported in Table 3 as mean + standard deviation for normal variables and 
median (25th, 75th percentiles) for variables with skewed distribution.  A comparison of the 
sample characteristics between the CRP cohort (n=201) and the rest of the WOMAN participants 
(n=307) revealed that the two groups were significantly different in the following variables: 
hormone therapy use and race (Tables 2).   
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Table 2 : Sample Characteristics 
Variable WOMAN 
CRP Cohort 
n=(201) 
WOMAN 
n=(307) 
p-value 
Race 
Caucasian 
Minorities 
 
93% 
7% 
 
88% 
12% 
p=0.0062* 
Education 
Some High School 
High School Graduate 
Some College 
College Graduate 
Advanced Degree 
 
1.5% 
15.5% 
30% 
26% 
 27% 
 
1% 
18% 
29% 
24% 
28% 
p=0.2621 
Current HRT Status 
On HRT 
Off HRT 
 
80% 
  20% 
 
60% 
40% 
p<0.0001* 
Current Smoking Status 
Smoke 
Do Not Smoke 
 
6% 
94% 
 
6% 
94% 
p=0.9125 
Past Smoking Status 
Smoked 
Did Not Smoke 
 
48% 
52% 
 
50% 
50% 
p=0.5811 
*p<0.05
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 Table 3: Baseline Measurements 
Variable CRP Cohort  n=(201) 
Physical Activity Measures 
Past Year Leisure PA (MET-hr/week) 
Total PA (MET-hr/week) 
Past Week Leisure PA (MET-hr/week) 
7-Day Mean Pedometer Steps 
Value 
11.87 (5.37, 19.63) 
16.08 (7.88, 30.63) 
10.20 (4.67, 17.83) 
6,345.30 (4801, 8918) 
Bloodwork 
Total Cholesterol (mmol/L) 
HDL-C (mmol/L) 
LDL-C (mmol/L) 
Triglycerides 
Glucose 
Insulin 
C-Reactive Protein 
 
208 + 23.95 
58.70 + 13.92 
119.11 + 19.70 
133 (99.0, 174.5) 
93.0 (88.0, 99.0) 
11.10 (8.9, 14.8) 
2.5 (1.6, 7.0) 
Physical Measurements 
Weight (pounds) 
Body Mass Index 
Waist Circumference 
Systolic Blood Pressure (mmHg) 
Diastolic Blood Pressure(mmHg) 
 
174.0 (158.0, 194.0) 
29.87 (27.10, 32.67) 
104.50 (98.8, 113.0) 
125.05 + 12.96 
76.35 + 8.59 
Subclinical Disease Measures 
Carotid IMT 
Coronary Calcium Score 
  0-10 
  >10 
 
0.7049 (0.6483, 0.7724) 
 
86% of cohort 
14% of cohort 
 
 46 
4.3 Specific Aim #1 
The purpose of this aim was to examine the relation between CRP and physical activity 
in postmenopausal women.  Three physical activity (PA) variables were obtained from the 
Modifiable Activity Questionnaire (MAQ) all expressed as MET-hr/week: 1) Past year leisure 
physical activity (LPA), 2) Total PA, and 3) Past week LPA.  The fourth physical activity 
variable was objectively measured in 75 subjects using the Yamax Digi-Walker pedometer.  A 
seven-day average of the number of the steps taken per day was calculated and expressed as 
steps/day.  In addition to the four collected PA variables, the data obtained during the past week 
LPA assessment was transformed from MET-hr/week to Mins/Wk and is included as a separate 
variable.  The physical activity measurements were strongly correlated to each other as 
illustrated in Table 4. 
Table 4: Spearman Correlations of Physical Activity Measures 
 Total PA Past Wk LPA Mean Steps Mins/Wk 
Past Yr LPA 0.6456 
p<0.0001 
0.3805 
p<0.0001 
0.3204 
p=0.0057 
0.3359 
p<0.0001 
Total PA  0.2983 
p<0.0001 
0.1932 
p=0.1015 
0.2529 
p=0.0003 
Past Wk LPA   0.4384 
p<0.0001 
0.8482 
p<0.0001 
Mean Steps    0.4876 
p<0.0001 
 
Spearman correlations revealed a significant inverse relationship between CRP and Mean 
pedometer steps (Table 5).   
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 Table 5: Correlation between CRP and Physical Activity 
 rho-value p-value 
Subjective   
Past Yr LPA 0.03082 0.6680 
Total PA 0.01287 0.8575 
Past Wk LPA -0.01348 0.8497 
Mins/Wk 0.0156 0.8265 
Objective   
Mean Steps -0.24413   0.0348* 
*p<0.05 
To examine the significant correlation between CRP and mean pedometer steps further, 
CRP was divided into two groups based upon clinically set standard values: <3.0 low/average 
risk (n=103) and >3.0 high risk (n=98).  Mean pedometer steps were divided into two groups: 
<6,000 (n=35) and >6,000 steps (n=40).  A chi square analysis revealed a significant relationship 
between the groupings of CRP and pedometer steps (p=0.0237).  Figure 1 illustrates the trend of 
pedometer steps across CRP.   
14.67%
30.67% 32%
22.67%
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
% of Population
<3.0 ≥3.0
CRP Level
<6,000 Steps
>6,000 Steps
 
Figure 1: Trend of Pedometer Steps Across CRP Levels 
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The relationship between pedometer steps as a continuous variable across CRP groups 
was investigated with regard to HRT.  For the women taking HRT, there was no significant 
difference (p=0.1447) in mean pedometer steps across CRP groups: CRP<3.0 (n=26), CRP>3.0 
(n=35).  There also was no significant difference (p=0.0528) in the women not taking HRT in 
mean pedometer steps across CRP groups: CRP<3.0 (n=8), CRP>3.0 (n=6).  Pedometer steps as 
a continuous variable by HRT status and CRP group is illustrated in Figure 2.     
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Figure 2: Pedometer Steps by HRT Across CRP Levels 
4.4 Specific Aim #2 
The purpose of the second specific aim was to determine the factors that are related to 
CRP in postmenopausal women.  The correlations between CRP and the independent variables 
which were included in the multivariate linear regression analysis were adjusted for age and 
hormone therapy use (Table 6).    Linear regression models were created with CRP as the 
dependent variable and the following independent variables: past year LPA, HRT status, age, 
smoking status, total cholesterol, waist circumference, body mass index, glucose, and insulin 
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(Table 7).  The model most related to CRP was found to be: past year physical activity, hormone 
therapy status, age, smoking status, total cholesterol, body mass index, and fasting glucose 
(model R2=0.1204). 
Table 6: Adjusted Correlations between CRP and Parameters 
 rho-value p-value 
Past Yr LPA 0.0588 0.4332 
Mean Pedometer Steps -0.1666 0.1882 
Waist Circumference 0.2212 0.0028* 
Body Mass Index 0.2931 <0.0001* 
Total Cholesterol -0.0237 0.7522 
HDL-Cholesterol -0.0701 0.3495 
Triglycerides 0.1472 0.0486* 
Glucose 0.0336 0.6540 
Insulin 0.0786 0.2945 
*p<0.05 
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Table 7: Multivariate Linear Regression Models for Leisure Physical Activity and CRP 
Model I Estimate + SE 
Past Year Leisure PA 
HRT Status 
Age  
Smoking Status 
Total Cholesterol 
Model R2
0.20 + 0.21 
-1.38 + 0.84 
0.06 + 0.12 
-1.87 + 1.51 
-0.01 + 0.01 
0.034 
Model II: Model I plus Waist Circumference  
Past Year Leisure PA 
HRT Status 
Age  
Smoking Status 
Total Cholesterol 
Waist Circumference 
Model R2
0.34 + 0.21 
-1.13 + 0.83 
0.08 + 0.12 
-2.23 + 1.48 
-0.02 + 0.01 
0.10 + 0.03** 
0.081 
Model III: Model I plus Body Mass Index  
Past Year Leisure PA 
HRT Status 
Age  
Smoking Status 
Total Cholesterol 
Body Mass Index 
Model R2
0.31 + 0.20 
-1.10 + 0.81 
0.11 + 0.12 
-2.65 + 1.46 
-0.02 + 0.01 
0.38 + 0.09*** 
0.114 
Model IV: Model III plus Glucose  
Past Year Leisure PA 
HRT Status 
Age  
Smoking Status 
Total Cholesterol 
Body Mass Index 
Glucose 
Model R2
0.32 + 0.20 
-0.95 + 0.82 
0.12 + 0.12 
-2.78 + 1.46* 
-0.02 + 0.01 
0.41 + 0.10*** 
-0.05 + 0.04 
0.1204 
*p<0.05; **p<0.01; ***p<0.001.  PA=Physical Activity. HRT=Hormone Therapy. CRP=C-reactive Protein. 
 
Another set of Linear regression models were created replacing past year leisure PA with 
mean pedometer steps.  The dependent variable was CRP and the independent variables 
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included: mean pedometer steps, HRT status, age, smoking status, total cholesterol, waist 
circumference, body mass index, glucose, and insulin (Table 8). 
Table 8: Multivariate Linear Regression Models for Mean Pedometer Steps and CRP 
Model I Estimate + SE 
Mean Pedometer Steps 
HRT Status 
Age  
Smoking Status 
Total Cholesterol 
Model R2
-0.0004 + 0.0002 
-1.90 + 1.54 
0.03 + 0.23 
-2.13 + 2.32 
0.003 + 0.03 
0.0898 
Model II: Model I plus Waist Circumference  
Mean Pedometer Steps 
HRT Status 
Age  
Smoking Status 
Total Cholesterol 
Waist Circumference 
Model R2
-0.0003 + 0.0002 
-1.70 + 1.55 
0.07 + 0.23 
-2.63 + 2.36 
0.002 + 0.03 
0.06 + 0.06 
0.1052 
Model III: Model I plus Body Mass Index  
Mean Pedometer Steps 
HRT Status 
Age  
Smoking Status 
Total Cholesterol 
Body Mass Index 
Model R2
-0.0003 + 0.0002 
-1.51 + 1.53 
0.13 + 0.23 
-3.61 + 2.39 
0.00002 + 0.03 
0.38 + 0.19 
0.1391 
Model IV: Model III plus Glucose  
Mean Pedometer Steps 
HRT Status 
Age  
Smoking Status 
Total Cholesterol 
Body Mass Index 
Glucose 
Model R2
-0.0002 + 0.0002 
-1.05 + 1.53 
0.11 + 0.23 
-3.36 + 2.37 
0.02 + 0.03 
0.44 + 0.19* 
-0.12 + 0.08 
0.1725 
*p<0.05; **p<0.01; ***p<0.001.  HRT=Hormone Therapy. CRP=C-reactive Protein. 
 52 
4.5 Specific Aim #3 
The purpose of this aim was to determine the association between CRP levels and 
coronary artery calcium score, carotid artery intimal thickness, and other cardiovascular risk 
factors in postmenopausal women.  Table 9 illustrates the correlations between CRP and the 
other cardiovascular parameters.  Significant positive correlations were identified between CRP 
and body mass index (rho=0.30810), waist circumference (rho=0.25707), and triglycerides 
(rho=0.19254).   
Table 9: Correlation between CRP & Parameters 
 
    rho-value p-value n 
 
Glucose   0.01695 0.5266  200 
Insulin    0.07371 0.3161  187 
Lipid Profile  
Total Cholesterol 0.01294 0.8556  200   
HDL-C  -0.07139 0.3151  200   
LDL-C  -0.04504 0.5266  200  
Triglycerides  0.19254 0.0063 * 200 
Body Mass Index  0.30810 <.0001* 201 
Waist Circumference  0.25707 0.0002* 201 
*p<0.05 
 
The interaction between CRP and BMI was analyzed.  Body mass index was divided into 
quartiles: <27 (n=44), 27-29.99 (n=61), 30-32 (n= 36), and >32 (n=60).  A significant linear 
relationship was observed between CRP continuously, and BMI quartiles (p=0.0008) as 
illustrated in Figure 3.   
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Figure 3: CRP Across BMI Quartiles 
 
To further analyze the relationship between CRP and body mass index, a chi square test 
was conducted.  CRP was divided into two groups based upon clinically set standard values: 
<3.0 low/average risk (n=103) and >3.0 high risk (n=98).  Body mass index was divided into 
quartiles: <27 (n=44), 27-29.99 (n=61), 30-32 (n= 36), and >32 (n=60).  The chi square analysis 
of CRP group * BMI group was statistically significant (p<0.0003; trend p<0.0001).    
C-reactive protein and carotid intimal medial thickness was analyzed utilizing a Kruskal-
Wallis statistic.  CRP was divided into two groups based upon clinically significant values: <3.0 
low/average risk (n=103) and >3.0 high risk (n=98).  Carotid intimal medial thickness was 
entered as a continuous variable.  There was not a significant relationship between CRP and 
intimal medial thickness (p=0.6012). 
A Chi Square analysis was conducted to investigate the relationship between CRP and 
coronary artery calcium score.  Again, CRP was divided into two groups based upon clinically 
significant values: <3.0 low/average risk (n=103) and >3.0 high risk (n=98).  The coronary artery 
calcium score variable was divided into two groups: 0-10 (n=172) and >10 (n=29) based upon 
the University of Pittsburgh Lab protocol.  There was not a significant relationship between CRP 
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and the coronary artery calcium score (p=0.4549).  The median CRP values are reported by 
groups in Table 10. 
Table 10: CRP Levels by CRP/CACS Group 
Group CRP Value 
CRP <3  and CACS:1-10 1.60 (1.0, 2.2) 
CRP <3 and CACS > 10 1.70 (1.3, 2.2) 
CRP >3 and CACS: 1-10 7.55 (5.3, 11.4) 
CRP >3 and CACS > 10 5.15 (4.4, 6.45) 
 
To further explore the relationship between coronary artery calcium score and all of the 
cardiovascular parameters, the cohort was divided into two groups: coronary calcium score 0-10 
(n=172), and coronary calcium score >10 (n=29).  Between group differences were analyzed 
with either Wilcoxon rank-sum tests, or t-tests for normally distributed variables.  Values in 
Table 11 are reported as mean + standard deviation for normal variables and median (25th, 75th 
percentiles) for variables with skewed distribution.  Overall, the women who had a coronary 
artery calcium score >10 had significantly higher glucose (p=0.0182), total cholesterol 
(p=0.0041), and LDL cholesterol (p=0.0119) levels.   
All parameters were also analyzed by dividing the cohort by hormone therapy use: On 
HRT (n=160) and Off HRT (n=41).  Women taking hormone therapy had significantly lower 
LDL-cholesterol (p=0.0363), glucose (p=0.0038), and diastolic blood pressure (p=0.0099) than 
those not taking hormone therapy.  Also, women taking hormone therapy had significantly 
higher levels of CRP (p=0.0216) than those women not on hormone therapy.  Between group 
differences were analyzed with either Wilcoxon rank-sum tests, or t-tests for normally 
distributed variables.  Values in Table 12 are reported as mean + standard deviation for normal 
variables and median (25th, 75th percentiles) for variables with skewed distribution. 
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 Table 11: Coronary Calcium Score Group Differences 
Variable Calcium Score 0-10  
n=172 
Calcium Score >10 
n=29 
p-value 
Physical Activity Measures 
Past Year Leisure PA (MET-hr/week) 
Total PA (MET-hr/week) 
Past Week Leisure PA (MET-hr/week) 
7-Day Mean Pedometer Steps 
 
11.69 (5.05, 19.26) 
15.86 (7.13, 31.07) 
10.31 (4.67, 18.50) 
6345 (4951, 8690) 
 
14.80 (8.38, 24.53) 
17.99 (8.98, 28.58) 
10.08 (4.67, 14.83) 
6218(4110, 9822) 
 
0.1719 
0.6877 
0.9117 
0.8231 
Bloodwork  
Total Cholesterol (mmol/L) 
HDL-C (mmol/L) 
LDL-C (mmol/L) 
Triglycerides 
Glucose 
Insulin 
C-Reactive Protein 
 
206.02 + 22.91 
58.90 + 14.24 
117.77 + 19.89 
133.0 (101.0, 169.0) 
92.0 (87.0, 98.0) 
11 (8.8, 14.4) 
2.5 (1.5, 7.3) 
 
219.66 + 26.49 
57.51 + 11.99 
127.0 + 16.75 
139.0 (98.0, 202.0) 
96.0 (92.0, 103.0) 
12.8 (10.0, 16.8) 
3.8 (2.1, 5.4) 
 
0.0041* 
0.5961 
0.0119* 
0.5513 
0.0182* 
0.1004 
0.9204 
Physical Measurements 
Weight (pounds) 
Body Mass Index 
Waist Circumference 
Systolic Blood Pressure (mmHg) 
Diastolic Blood Pressure (mmHg) 
 
173.5 (157.5, 192.75) 
29.73 (27.04, 32.52) 
104.0 (98.35, 113.3) 
124.31 + 12.73 
76.15 + 8.26 
 
174.5 (162.5,200.0) 
30.40 (27.83, 35.18) 
106.8 (99.8, 110.7) 
129.45 + 13.63 
77.52 + 10.40 
 
0.3998 
0.1417 
0.6906 
0.0602 
0.4212 
Subclinical Disease Measures 
Carotid IMT 
 
 
0.6991 (.6473, .7694) 
 
 
0.7356 (.6552, .8132) 
 
0.1434 
*p<0.05 
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Table 12: Group Differences by Hormone Therapy Use 
Variable On HRT 
n=160 
Not On HRT 
n=41 
p-value 
Physical Activity Measures 
Past Year Leisure PA (MET-hr/week) 
Total PA (MET-hr/week) 
Past Week Leisure PA (MET-hr/week) 
 
12.03 (5.54, 19.65) 
16.52 (9.18, 31.23) 
10.79 (5.50, 18.78) 
 
11.30 (3.77, 18.92) 
15.38 (4.62, 29.37) 
8.46 (3.79, 13.79) 
 
0.7832 
0.3342 
0.0644 
7-Day Mean Pedometer Steps 6251 (4951, 8690) 6587(4110, 9799)  
Bloodwork  
Total Cholesterol (mmol/L) 
HDL-C (mmol/L) 
LDL-C (mmol/L) 
Triglycerides 
Glucose 
Insulin 
 
207.42 + 24.47 
58.91 + 13.74 
117.72 + 20.06 
140.0 (102.0, 176.0) 
92.0 (87.0, 98.0) 
11.0 (9.0, 15.20) 
3.4 (1.85, 7.10) 
 
210.27 + 21.94 
57.89 + 14.74 
124.46 + 17.47 
 
0.4711 
0.6898 
0.0363* 
0.0684 
0.0038* 
0.9934 
113.0 (98.0, 150.0) 
98.0 (90.0, 103.0) 
11.85 (8.35, 14.5) 
C-Reactive Protein 1.70 (1.2, 4.7) 0.0216* 
Physical Measurements 
Weight (pounds) 
Body Mass Index 
Waist Circumference 
Systolic Blood Pressure (mmHg) 
 
175.0 (158.5,194.3) 
29.46 (26.76, 31.89) 
102.5 (97.0, 110.5) 
126.29 + 12.50 
 
0.8463 
0.3963 
0.2853 
0.4824 
 
173.0 (157.8, 193.5) 
29.90 (27.11, 32.85) 
105.30 (98.8, 113.3) 
124.73 + 13.09 
75.63 + 8.76 79.17 + 7.33 Diastolic Blood Pressure (mmHg) 0.0099* 
Subclinical Disease Measures 
Carotid IMT 
Coronary Calcium Score 
 0-10 
  
0.7006 (.6473, .7694) 
 
69% of cohort 
 
0.7060 (.6489, .7871) 
 
17% of cohort 
3% of cohort                               > 10 11%  of cohort 
*p<0.05 
0.7482 
4.6 Specific Aim #4 
The purpose of this aim was to determine the factors that are related to the coronary 
artery calcium score in postmenopausal women.  A logistic stepwise regression analysis was 
completed with coronary artery calcium score as the dependent variable and the following 
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independent variables:  CRP, past year LPA, carotid artery intimal medial thickness, total 
cholesterol, HDL-cholesterol, triglycerides, waist circumference, HRT status, and age.  Past year 
LPA was forced into the model and all other variables were left in the model at the 0.05 
significance level.  The best subset of related factors for coronary artery calcium score (Table 13) 
was found to be: past year LPA, and average waist circumference (model p=0.0356). 
Table 13: Logistic Stepwise Regression Model for Coronary Artery Calcium Score 
 
Model1 Estimate + SE P value 
Past Year LPA 0.0946 + 0.0933 0.3109 
Waist Circumference 0.0541 + 0.0154 0.0004 
 
 
1Variables in order of entry into multiple regression model 
4.7 Specific Aim #5 
The purpose of this aim was to identify subjects with characteristics of metabolic 
syndrome and to determine if there were differences in CRP, coronary artery calcium score, 
carotid artery intimal thickness, and physical activity among those women without metabolic 
syndrome.  According to the ATP III guidelines, a woman would be classified as having 
metabolic syndrome if they exhibited any three or more of the following criteria: 1) waist 
circumference >88 cm, 2) serum triglycerides > 1.7 mmol/L, 3) blood pressure >130/85 mmHg, 
4) HDL cholesterol <1.3 mmol/L, and 5) serum glucose >6.1 mmol/L (32).  In this cohort, 38% 
of the women (n=76) had characteristics of metabolic syndrome while 62% (n=125) did not.  
Table 14 outlines the distribution of the cohort with regards to the number of characteristics of 
metabolic syndrome.   
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Table 14: Frequency Table of Metabolic Syndrome Characteristics 
# of Characteristics < 1  2 3 >4 
n (%) 56 (28) 68 (34) 53 (26.5) 23 (11.5) 
Between group differences were analyzed with either Wilcoxon rank-sum tests, or t-tests 
for normally distributed variables.  Values in Table 15 are reported as mean + standard deviation 
for normal variables and median (25th, 75th percentiles) for variables with skewed distribution.   
Table 15: Group Differences by Metabolic Syndrome Classification 
Variable No Met. Syndrome 
n=125 
Met. Syndrome 
n=76 
p-value 
Physical Activity Measures 
Past Year Leisure PA (MET-hr/week) 
Total PA (MET-hr/week) 
Past Week Leisure PA (MET-hr/week) 
 
12.81 (5.18, 19.65) 
17.01 (8.28, 35.49) 
10.79 (5.38, 19.60) 
 
11.17 (5.63, 18.80) 
15.77 (7.25, 27.86) 
9.54 (3.77, 15.12) 
 
0.5040 
0.6752 
0.1278 
7-Day Mean Pedometer Steps 6251 (5105, 10139) 6381(4526, 7887) 0.2902 
Bloodwork  
Total Cholesterol (mmol/L) 
HDL-C (mmol/L) 
LDL-C (mmol/L) 
Triglycerides 
Glucose 
Insulin 
*p<0.05 
C-Reactive Protein 
 
204.46 + 23.68 
63.26 + 13.13 
118.18 + 20.51 
111.50 (89.0, 140.0) 
91.50 (87.0, 95.0) 
10.70 (8.3, 13.70) 
2.5 (1.5, 7.1) 
 
213.78 + 23.39 
51.26 + 11.87 
120.62 + 18.34 
 
0.0072* 
<0.0001* 
0.3839 
<0.0001* 
<0.0001* 
0.0183* 
179.0 (153.5, 240.0) 
98.0 (91.5, 103.0) 
12.95 (9.40, 16.85) 
3.15 (1.85, 6.30) 0.4509 
Physical Measurements 
Weight (pounds) 
Body Mass Index 
Waist Circumference 
Systolic Blood Pressure (mmHg) 
 
179.75 (158.0, 201.5) 
31.12 (27.33, 34.15) 
106.95 (99.0, 116.9) 
129.66 + 12.37 
 
0.1764 
0.0210* 
0.0942 
<0.0001* 
 
170.5 (158.0, 191.0) 
28.69 (27.07, 31.86) 
103.70 (98.3, 110.8) 
122.25 + 12.54 
75.39 + 7.93 77.92 + 9.42 Diastolic Blood Pressure (mmHg) 0.0524 
Subclinical Disease Measures 
Carotid IMT 
Coronary Calcium Score 
  0-10 
  
0.6899 (.6483, .7583) 
 
56% of cohort 
 
0.7287 (.6473, .7966) 
 
29% of cohort 
9% of cohort                                >10 6%  of cohort 
0.0378* 
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When compared to those women without characteristics of metabolic syndrome, women 
with metabolic syndrome had significantly lower HDL-cholesterol levels (p<0.0001) and higher 
total cholesterol (p=0.0072), triglycerides (p<0.0001), glucose (p<0.0001), and insulin 
(p=0.0183) levels.  These women also had significantly higher body mass index (p=0.0210), 
systolic blood pressure (p<0.0001), and carotid intimal medial thickness (p=0.0378).  Lastly, 
coronary artery calcium score and the prevalence of metabolic syndrome was investigated.  A 
Chi Square analysis: metabolic syndrome * coronary calcium score was conducted.  There was a 
significant relationship between the two parameters (p=0.0125). 
 To better examine the characteristics of those women with metabolic syndrome, the 
metabolic syndrome characteristics were divided into four groups: <1 (n=56), 2 (n=68), 3 
(n=53), and >4 (n=23).  The group differences by metabolic syndrome characteristics are 
presented in Table 16.  As the number of characteristics increased, a significant increase was also 
observed in total cholesterol (p=0.0431), triglycerides (p<0.0001), glucose (p<0.0001), insulin 
(p= 0.0010), body mass index (p=0.0037), and systolic blood pressure (p=0.0007).  Also, HDL-
cholesterol significantly decreased (p<0.001) as the number of metabolic syndrome 
characteristics increased. 
The subclinical disease measures were also examined with regards to the number of 
characteristics of metabolic syndrome.  Carotid artery intimal medial thickness was not 
statistically different among the number of metabolic syndrome characteristics (p=0.1878).  The 
median intimal medial thickness of the carotid artery for each characteristic group is illustrated in 
Figure 5.  There was also, no significant difference in coronary artery calcium score was 
observed between the number of metabolic syndrome characteristics (p=0.0674, trend 
p=0.0452).   
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Table 16: Group Differences by Metabolic Syndrome Characteristics 
 >1 
n=56 
2 
n=68 
3 
n=53 
>4 
n=23 
Physical Activity Measures 
Past Year Leisure PA 
         (MET-hr/week) 
Total PA (MET-hr/week) 
Past Week Leisure PA  
        (MET-hr/week) 
7-Day Mean Pedometer Steps 
 
14.37 (5.35, 21.81) 
 
17.75 (9.76, 34.63) 
12.25 (5.25, 21.46) 
 
6251 (5111, 101461) 
 
11.64 (5.07, 19.0) 
 
15.82 (7.12, 49.34) 
10.23 (5.08, 18.14) 
 
6128 (4732, 9822) 
 
10.26 (4.62, 19.17) 
 
15.71 (6.46, 27.86) 
9.58 (3.79, 15.28) 
 
5687 (4308, 7060) 
 
11.74 (8.3, 17.62) 
 
15.77 (9.28, 28.99) 
9.50 (2.92, 14.96) 
 
7032 (4526, 8690) 
Bloodwork  
Total Cholesterol (mmol/L) * 
HDL-C (mmol/L) **** 
LDL-C (mmol/L) 
Triglycerides **** 
Glucose **** 
Insulin *** 
C-Reactive Protein 
 
201.63 + 23.95 
64.51 + 10.60 
116.80 + 22.34 
103.50 (80.0, 127.0) 
90.0 (85.5, 93.0) 
10.15 (7.4, 11.95) 
2.3 (1.2, 6.85) 
 
206.79 + 23.38 
62.23 + 14.90 
119.31 + 18.96 
123.0 (99.0, 146.5) 
92.0 (88.0, 98.0) 
11.80 (9.6, 15.90) 
3.8 (1.75, 7.40) 
 
212.79 + 20.27 
54.02 + 12.88 
120.75 + 18.33 
175.0 (140.0, 233.0) 
97.0 (91.0, 103.0) 
11.65 (9.30, 14.80) 
2.40 (2.1, 6.40) 
 
216.04 + 29.78 
44..90 + 5.23 
120.30 + 18.77 
196.0 (168, 276) 
101.0 (92.0, 107.0) 
13.65 (10.8, 20.40) 
4.8 (1.4, 6.2) 
Physical Measurements 
Weight (pounds) 
Body Mass Index ** 
Waist Circumference 
Systolic Blood Pressure (mmHg)*** 
Diastolic Blood Pressure (mmHg) 
 
166.25 (152.3, 187.5) 
28.08 (26.72, 31.43) 
103.60 (96.2, 109.7) 
120.41 + 11.08 
74.79 + 7.84 
 
178.25 (163.0, 194.2) 
29.93 (27.54, 32.14) 
104.15 (99.95, 113.3) 
123.71 + 13.61 
75.82 + 8.07 
 
176.0 (157.5, 200.0) 
30.38 (26.42, 33.40) 
104.80 (98.8, 116.8) 
130.38 + 12.46 
78.11 + 9.59 
 
188.0 (164, 213) 
32.3 (29.7, 35.4) 
108.3 (99.8, 117.8) 
128.0 + 12.28 
77.48 + 9.21 
Subclinical Disease Measures 
Carotid IMT 
Coronary Calcium Score 
  0-10 
  >10 
 
0.6866 (.6499, .7401) 
 
24% of cohort 
3.5%  of cohort 
 
0.7079 (.6440, .7695) 
 
31% of cohort 
2.5% of cohort 
 
0.7325 (.6331, .8131) 
 
21% of cohort 
6% of cohort 
 
.7249(.6676,.7694) 
 
9% of cohort  
3% of cohort 
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
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Figure 4: Median IMT Across Metabolic Syndrome Groups 
 
 62 
5.0  DISCUSSION 
5.1 Introduction 
The primary purpose of this study was to examine the associations between C-reactive 
protein (CRP) and physical activity on the risk factor profile of postmenopausal women without 
known heart disease who were either taking or not taking hormone therapy.  The secondary 
purpose of this investigation was to examine the relation of other cardiovascular risk factors on 
subclinical measures of coronary heart disease (CHD).   
A cohort of 201 females who were participating in the WOMAN study was used for this 
investigation.  All of the women were postmenopausal and most (80%) at the time of the 
collection of the baseline data were taking HRT.  The majority of the sample was Caucasian 
(93%) and educated with 83% having at least some college education or completing college 
degrees.  On average, the cohort had a lipid profile within normal range per ATP III Guidelines 
and an “average risk” CRP level.  As a cohort, the women were overweight with a body mass 
index of 29.87 and a waist circumference of 104.5-cm which is not surprising due to the study 
inclusion criteria.  To participate in the WOMAN study, their waist circumference had to be >80 
centimeters.   
The baseline data obtained on this cohort was analyzed for this investigation and the 
results will be discussed in the following sections: 1) Physical activity & CRP, 2) CRP & 
Cardiovascular Risk Markers, 3) HRT & Cardiovascular Risk Markers, 4) Coronary Artery 
Calcium Score, and 5) Metabolic Syndrome. 
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5.2 Physical Activity & CRP 
As previously mentioned, coronary heart disease is increasingly being viewed as an 
inflammatory process and that high sensitivity C-reactive protein, a marker of inflammation, 
becomes elevated with atherogenesis and therefore can aid in prediction of CHD risk (54).  It is 
widely recognized that physical activity can aid in the prevention of CHD and there is evidence 
that higher levels of physical activity are associated with lower levels of C-reactive protein 
(1,25).  Although, the physiological mechanism responsible for this pattern is unclear, one could 
hypothesize that physical activity reduces the risk of CHD by reducing or preventing the 
inflammatory process.   
In this cohort of postmenopausal women, there was not a significant relationship between 
self-reported subjective measures of physical activity and CRP levels.  Three subjective physical 
activity variables were obtained from the Modifiable Activity Questionnaire: 1) Past year LPA, 
2) Total PA, and 3) Past week LPA.  Of the three, only past week LPA had a very weak inverse 
association (rho= -0.01348) with CRP.  A fourth physical activity variable, pedometer steps, was 
objectively measured and did have a significant inverse relationship with CRP (rho= -0.24413).   
The inconsistencies observed between the subjective and objective measures of physical 
activity may be due to many factors.  First, the PA measures utilized in this study capture 
different intensities of exercise.  The MAQ physical activity questionnaire captures moderate to 
high levels of physical activity as compared to the pedometer.  The pedometer is an accurate tool 
for measuring activities of daily living (lower intensity), however, does not capture cycling, 
water activities, and arm movement.  Thus, the inconsistent findings could be a product of 
methodological precision.   
Second, unlike the three subjective PA measures which were obtained on 201 subjects, 
pedometer step counts were only collected on 75 women in this cohort.  Another possible 
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explanation for these inconsistencies among PA measures could be due to the relatively small 
sample size; therefore, the strength of the relationship may have been weakened.  If all of the 
physical activity measures had been collected on equal amounts of study participants, 
comparison among the measures would be more revealing.      
Third, there might not have been a strong association between CRP levels and physical 
activity observed in this study because of the activity level of the cohort.  As a whole, they 
completed a median of 16.08 (7.88, 30.63) MET-hrs per week of physical activity.  To get a 
better look at the volume of exercise completed, the data obtained during the past week LPA 
assessment was transformed from MET-hr/week to Mins/Wk which reveled that the women 
completed a median of 140 (60, 220) mins/wk of moderate physical activity.  Also, as recorded 
by the pedometer they walked a median of 6,345.30 (4,801, 8,918) steps per week.  Current 
recommendations for physical activity as per the United States Surgeon General suggest that 
individuals accumulate at least 30 minutes of moderate physical activity on most days of the 
week (approximately 150 mins/wk) (86).  Pedometer indices for public health have been created 
and can be used to classify adults into the following activity levels: 1) <5,000 steps/day – 
Sedentary, 2) 5,000-7,499 steps/day – Low active, 3) 7,500-9,999 steps/day –Somewhat active, 
and 4) > 10,000 steps/day –Active (97).  Thus, in comparison to public health standards, this 
cohort of women was low-active.  Perhaps, if there was a larger range of activity levels within 
the cohort, a stronger association would have been observed between CRP and PA.     
Overall, in the research investigating CRP and physical activity, two distinct and 
conflicting conclusions have been supported.  The first is that there is an inverse relationship 
between CRP and physical activity supporting the hypothesis that physical activity may reduce 
inflammation (5, 25).  This relationship remained after adjusting for confounding variables 
including BMI and waist-hip ratio (5, 25).  The second conclusion from previous research 
 65 
suggests that the relationship between CRP and physical activity is not as strong as the impact of 
body mass index and adiposity on CRP levels (71, 97).   
The results of the present investigation show that physical activity may play a role in 
CRP levels as objectively measured by pedometer steps but also suggests that anthropometic 
measures have a significant impact on CRP levels.  Overall, physical activity was significantly 
related to the anthropometric measures.  Past year physical activity was inversely related to waist 
circumference (rho= -.019014).  Also, there was a significant inverse relationship between mean 
pedometer steps and body mass index (rho= -0.33990) as well as to waist circumference (rho= -
0.26009).  Due to these varied results within previous research and within this current 
investigation, more research investigating CRP and its relationship with physical activity and 
adiposity is warranted.   
5.3 CRP & Cardiovascular Risk Markers 
The relationship between CRP and other cardiovascular risk markers was investigated.  
In this cohort, significant positive correlations were identified between CRP and body mass 
index (rho=0.30810), waist circumference (rho=0.25707), and triglycerides (rho=0.19254).  In 
the group of women who had a CRP level >3.0 (high relative risk), a significantly larger 
proportion of them had a BMI > 29.9.  In this investigation, the best subset of predictors for CRP 
was found to be average waist circumference, smoking status, past year physical activity, and 
total cholesterol levels.  These results also support the theory that adiposity is strongly linked to 
CRP levels.   
As mentioned earlier, obesity has multiple roles in triggering the inflammation associated 
with atherogenesis.  Not only does obesity increase the risk of insulin resistance and diabetes, but 
it also contributes to dyslipidemia; all which may cause inflammation (54).  Obesity directly 
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increases inflammation due to adipose tissue synthesizing proinflammatory cytokines such as 
interleukin-6, a primary hepatic stimulant for CRP production (107).   
5.4 HRT & Cardiovascular Risk Markers 
The present cohort was divided into two groups consisting of those who were taking HRT 
(n=113), and those who were not (n=88).  The women taking HRT had significantly lower LDL-
cholesterol (117.72 + 20.06 mmol/L), glucose [92.0 (87.0, 98.0)], and diastolic blood pressure 
(75.63 + 8.76 mmHg) and significantly higher levels of CRP [3.4 (1.85, 7.10)] than the women 
who were not taking HRT. 
Previous research has supported the results of this current investigation.  Generally, 
estrogen replacement has been shown to decrease total cholesterol and LDL cholesterol while 
increasing HDL cholesterol and triglycerides.  Also, women taking HRT have been found to 
have elevated CRP levels.  The study conducted by Manns et al. (2003) found that the median 
CRP levels for women on hormone therapy (with or without progestin) was 3.5 – 5.5 times 
higher than those not taking hormone therapy.   
In a different study, investigators examined the hypothesis that hormone replacement 
therapy related increases in CRP would either be blunted or absent in those postmenopausal 
women who regularly exercised (95).  Plasma CRP levels were ~75% higher in the sedentary 
group who were hormone therapy users when compared to sedentary non-users.  There was no 
significant difference in CRP levels between hormone therapy groups for the physically active 
women. The researchers concluded that since the elevation in CRP due to hormone replacement 
therapy observed in sedentary women is absent in women who engage in regular physical 
activity, physical activity may prevent the increase in CRP secondary to hormone replacement 
therapy (95).  
 67 
In the cohort from the WOMAN study, there were no differences in physical activity 
between those women taking HRT and those not on HRT.  It should be noted however that 80% 
of the cohort was on HRT thus possibly minimizing the between group differences.    
5.5 Coronary Artery Calcium Score 
Coronary calcification as measured by EBCT has been shown to be associated with 
traditional risk factors of coronary artery disease in women (24, 47).  In both of these 
investigations, most of the traditional risk factors were associated with the coronary calcium 
score after adjustment for age and gender.  Coronary calcification was associated with LDL-
cholesterol, HDL cholesterol, systolic blood pressure, glucose, trigylcerides, body mass index, 
and cigarette smoking (24, 47).   
In this current research project, to investigate the relationship between coronary 
calcification and other cardiovascular risk markers, the cohort was divided into two groups based 
upon the coronary calcium score: 0-10, or >10.  According to the University of Pittsburgh EBCT 
lab, coronary calcium scores ranging from 0-10 have limited clinical value.  Therefore it was 
recommended that this dichotomous grouping be used.  The women who had coronary 
calcification scores greater than 10 had significantly higher glucose, total cholesterol, and LDL 
cholesterol levels than those women with coronary calcium levels <10.  There was no significant 
association between coronary calcification and CRP.  An analysis was completed to find the best 
subset of related factors for coronary artery calcium score. The model reveled that past year 
LPA, and average waist circumference were the best predictors of the coronary artery calcium 
score. 
The association of nontraditional cardiovascular risk factors with coronary artery 
calcification was examined in a cohort of the Atherosclerosis Risk in Communities (ARIC) 
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Study (24).    Interestingly, the researchers did not find significant associations between the 
coronary calcium score and sports physical activity, insulin, nor with the inflammation marker 
CRP.  Similarly, in the present investigation, only the traditional cardiovascular risk factors were 
associated with coronary calcification and no evidence was found for the inclusion of the “non-
traditional” risk factors in the overall CHD risk assessment model.     
5.6 Metabolic Syndrome 
Since most instances of premature CHD occur in women who have a clustering of risk 
factors as seen in the “metabolic syndrome”, these individuals should be targeted for more 
intensive cardiovascular risk reduction. According to the ATP III guidelines, a woman would be 
classified as having metabolic syndrome if they exhibited any three or more of the following 
criteria: 1) waist circumference >88 cm, 2) serum triglycerides > 1.7 mmol/L, 3) blood pressure 
>130/85 mmHg, 4) HDL cholesterol <1.3 mmol/L, and 5) serum glucose >6.1 mmol/L (32). 
Based upon these guidelines, the cohort in this investigation was divided into two groups: 
those with characteristics of metabolic syndrome (n=76), and those without (n=125).  Between 
group differences were analyzed.  Expectedly, those women with metabolic syndrome had 
significantly lower HDL-cholesterol, higher triglycerides and glucose levels.  Also, those with 
metabolic syndrome were found to have higher total cholesterol levels, insulin levels, body mass 
index, systolic blood pressure, and carotid intimal medial thickness.  There was not a statistically 
significant difference in CRP levels between groups; however those women in the metabolic 
syndrome group had a median CRP level of 3.15 which is considered high relative risk as 
compared to those without (CRP level of 2.5, normal risk).     
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5.7 Limitations and Recommendations for Future Research 
This study is not without limitations and these may minimize the application of these 
findings.  Future studies should address these factors to improve the generalizability and impact 
of these findings. 
1)  This was a cross-sectional investigation of a cohort of women participating in the 
WOMAN study.  A longitudinal analysis may better show the associations between CRP and 
physical activity on the risk factor profile of postmenopausal women.   Also, a longitudinal 
design would be better to look at the predictive value of cardiovascular risk factors on subclinical 
measures of coronary heart disease. 
2)  Although physical activity was measured both subjectively and objectively in this 
investigation, a much smaller sample of the cohort (37%) completed the objective pedometer 
step measurement.  Future research should equally collect physical activity variables both 
subjectively through questionnaires and objectively using a tool such as a pedometer.  Also, 
future research could include other objective measures of physical activity such as an 
accelerometer, the Body Media armband, and/or doubly-labeled water.  A physical activity index 
utilizing the Ratings of Perceived Exertion (RPE) Scale and pedometer step count could be 
utilized to quantify the total aerobic exercise training load.  
3)  In this investigation, the women may not have been a true representation of all post-
menopausal women due to the inclusion criteria of the WOMAN study.  For inclusion, the waist 
circumference was >80cm, thus this population could have had more waist adiposity than the 
general population.  This could have limited the effect of physical activity on CRP.  Future 
research should investigate the relationship between physical activity and CRP without any body 
measurement inclusion criteria, therefore increasing generalizability of the results. 
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4)  This cohort of women was 93% Caucasian and educated.  Therefore the 
generalizability of the findings is limited to women with similar demographics to the subjects 
who participated in this investigation.  In future research, ethnic differences could be 
investigated with regard to CRP, and cardiovascular risk factors in general.   
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WOMAN Study 
Participant Information  
 
Please only complete lines where there are changes from last visit. 
ID:_________________       
 
Date:_____/_____/_____(MM/DD/YY)     
Staff:_______________ 
 
Name:_______________________________________________________________________________ 
 
Address:_____________________________________________________________________________ 
 ______________________________________________________________________________ 
 
Phone #: (Home)_(____)______________________ 
  (Work)_(____)______________________ 
  (Other)_(____)______________________ 
Email:  ___________________________________ 
 
Alternative Contact:___________________________________Phone  (Home): _(____)___________ 
(Preferably somebody who does not live with you) 
Relation to Participant:_________________________________ (Work):  _(____)___________ 
 
Emergency Contact:___________________________________Phone  (Home): _(____)___________ 
 
Relation to Participant:_________________________________ (Work):  _(____)___________ 
 
Primary Physician’s Name:______________________________________________________________ 
 
Address:_____________________________________________________________________________ 
              _____________________________________________________________________________ 
 
PCP_Phone#:_(____)_____________________________
 74 
          ID ____________ 
          Date___________ 
 
The WOMAN on the Move Study 
 
HEIGHT, WEIGHT, AND WAIST  MEASUREMENTS:       
1. Standing Height- Record to nearest half-inch 
 (round up) without shoes:      ____. ____inches 
          ____._____cm 
2. Weight - record to nearest half-pound, (round up) 
 clothed, without shoes:       _____. ____lbs. 
_____._____kg.  
WAIST MEASUREMENTS (cm) - Record to nearest (.1) cm 
1st reading_______________           2nd reading_______________ 3rdreading_______________ 
 
If first 2 readings are within 2 cm, average the 2.  If not, do a third measurement and average the 2 
measures within range (2 cm). If even after 3 measures there are no matches, take the average of the 2 
closest measurements. 
 
3. Average waist circumference _____. ___cm       
 (> 80 cm–eligible)  
 
HEART RATE 
4.   Beats in 30 seconds: __________X2 = __________ 
 
BLOOD PRESSURE MEASUREMENTS: 
Cuff Size: ____ Regular  ____Large  ____Pediatric  _____Thigh 
Arm: _____Left _____Right 
 
 
5. First Reading     __________/___________ 
                                  Systolic         Diastolic 
6.   Second Reading __________/___________ 
       Systolic Diastolic 
7. Average of blood pressure Readings__________/___________ 
       Systolic    Diastolic 
 
ID ______________ 
 
BLOOD DRAW (12 HOUR FAST) 
8.      When did you last have anything other than water to eat or drink?  _________ a.m./p.m. 
Note:If less than 10 hours from clinic appointment, participant should be rescheduled for the blood draw. 
Time Blood Drawn: __________ a.m./p.m. 
 
 Difficult blood draw?  1. □Yes  2.  □No 
 
 Was blood sample collected? 1.  □Yes 2. □ No, specify reason 
 
 Tubes collected: (Τ if completed) 
EDTA 10mL:    _______ 
  Serum 15 mL:   _______ 
  Serum 10 mL:   _______ 
  Na Nitrate 5mL:_______ 
 
MEDICATION(S) LIST       Office Use Only 
9.   Over the past 2 weeks have you taken any prescribed medications? # meds ______ 
 1. □Yes     2. □ No 
 
Medication 1:    Medication 2:   Medication 3:  
 
Type _________________          Type _________________ Type_________________                   
      
Date began________mo/yr          Date began________mo/yr Date began________mo/yr 
  
Dose_______________mg          Dose_______________mg  Dose_______________mg 
      
Freq._________________x /day         Freq.________________x /day Freq._______________x /day 
      
Reason___________________          Reason__________________        Reason__________________     
 
 
Medication 4:    Medication 5:   Medication 6:  
 
Type _________________          Type _________________ Type_________________                   
      
Date began________mo/yr          Date began________mo/yr Date began________mo/yr 
  
Dose_______________mg          Dose_______________mg  Dose_______________mg 
      
Freq._________________x /day         Freq.________________x /day Freq._______________x /day 
      
Reason___________________          Reason__________________        Reason__________________     
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Medication 7:    Medication 8:   Medication 9:  
 
Type _________________          Type _________________ Type_________________                   
      
Date began________mo/yr          Date began________mo/yr Date began________mo/yr 
  
Dose_______________mg          Dose_______________mg  Dose_______________mg 
      
Freq._________________x /day         Freq.________________x /day Freq._______________x /day 
      
Reason___________________          Reason__________________        Reason__________________     
9a. Do you take aspirin (not Tylenol): (0) □ daily 
      (1) □ 1-6 times/week 
      (2) □ less than once/week 
      (3) □ rarely 
      (4) □ never (go to blood results) 
9b. When you take aspirin, how many on the average do you take per day?_______per day 
 
9c. How many aspirin have you taken in the last 48 hours  ______aspirin 
        (00 if none) 
HORMONE REPLACEMENT USE 
10.   Are you currently taking hormone therapy?  1.  □ Yes (if yes, proceed to #11)  2.  □ No 
 
10a. If no, what was the date that you stopped taking HRT? _______(MM/YY) (proceed to #13) 
 
11. What are the hormones that you are taking? 
 
Hormone 1: (Please circle one)   Hormone 2: (Please circle one) 
Oral Patch Injection Other   Oral  Patch  Injection Other 
 
Name__________________________  Name_______________________________ 
Date Began_____________(MM/YY)  Date Began__________________(MM/YY) 
Dose________________________mg  Dose_____________________________mg 
Days/Month____________________  Days/Month_________________________ 
Months Taken___________________  Months Taken________________________ 
 
Hormone 3: (Please circle one)   Hormone 4: (Please circle one) 
Oral Patch Injection Other   Oral  Patch  Injection Other 
 
Name__________________________  Name_______________________________ 
Date Began_____________(MM/YY)  Date Began__________________(MM/YY) 
Dose________________________mg  Dose_____________________________mg 
Days/Month____________________  Days/Month_________________________ 
Months Taken___________________  Months Taken________________________ 
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12.   Have you stopped taking your hormones in the past year for more than 1 week? 
    1.  □ Yes        2.  □ No | Go to #14 
          a. If yes, how many occasions did you stop taking your hormones? _____ (Proceed to #14) 
 
13.   What were the primary reasons you stopped taking hormone replacement therapy?  (Check all 
that apply) 
  □ Directed by physician 
  □ Needed second opinion from another doctor 
  □ Felt like I didn’t need it 
  □ Thought the medication was harmful 
  □ The cost of the medication  
  □ Developed a new health problem 
  □ Heard about the Women’s Health Initiative HRT results and decided to stop  
   because of health risks 
  □ Had undesirable side effects (check all that apply below): 
    ___ Weight gain   ___ Depression/mood swings 
    ___ Bleeding    ___ Flu-like symptoms 
    ___ Breast lumps   ___ Headaches 
    ___ Breast tenderness  ___ Other______________ 
  □ Other (please specify)_________________________________________ 
 
14.       Have you experienced any side effects while on HRT?  
  1.  □ Yes      2.  □ No 
 (if yes,   check all that apply below) 
 
____Weight gain  ____Depression/mood swings 
____Bleeding   ____Flu-like symptoms 
____Breast lumps  ____Headaches 
____Breast tenderness  ____Other_________________ 
 
15. Do you currently smoke? 
1. □ Yes 2. □ No 
 
16. Have you had a mammogram in the last year? 
1. □ Yes 2. □ No      1a.   If yes, Date: _____/_____mo/yr  
If no, explain importance of mammography and where to have them done 
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17. Have you ever been diagnosed by a physician with cancer? 
1. □ Yes 2. □ No (If no, proceed to #18) 
       17a.   If yes, Date: _____/_____mo/yr 
 17b.   If yes, which type? 
  □ Breast 
  □ Uterine (Endometrium) 
  □ Ovary 
  □ Other, describe _________  
 
18. Have you had a cardiovascular event since the start of your participation in this study?   
1. □ Yes 2. □ No (If no, questionnaire, go to #19) 
18a.   If yes, which type of event? 
 □  Myocardial infarction; Date:______/______mo/yr 
 □  Stroke; Date:______/______mo/yr 
 □  Venous thrombosis: Date:______/______mo/yr 
 □  Aneurysm, in what location (e.g.,aortic)?__________; Date:_____/____mo/yr 
 □  Other?, describe_________________________; Date:______/______mo/yr 
 
19. Has your doctor ever told you that you have: 
 Arthritis   1. □ Yes 2. □ No 
 Diabetes (Sugar)  1. □ Yes 2. □ No 
 Lung Disease   1. □ Yes 2. □ No 
 Kidney Disease  1. □ Yes 2. □ No 
 Pancreatitis   1. □ Yes 2. □ No 
 Gallstone   1. □ Yes 2. □ No 
 Thyroid Disease  1. □ Yes 2. □ No 
 
20. Have you ever had gastric bypass surgery? 
1. □ Yes 2. □ No   
 If yes; Date:________/________mo/yr 
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 ID_____________                                   
Corridor Walk 
Exclusion Questions 
Script: “The following tests will assess your physical fitness by having you walk 1/4 mile at a steady pace.  
First I need to ask you a few questions to see if you should try the test.” 
a.  Does the participant use a walking aid, such as a cane?   Yes   No 
 
b.  Within the past 3 months, have you had a heart attack?     Yes   No 
 
c.  Within the past 3 months, have you had angioplasty?    Yes   No 
 
d.  Within the past 3 months, have you had heart surgery?   Yes   No 
 
e.  Within the past 3 months, have you had any new or 
     worsening heart pain or angina?      Yes   No 
 
Demonstration   
a.  Attachment for heart rate monitor: 
Script: “This device measures your pulse, or how often your heart beats.” 
 
400-Meter Walk Test Performance 
Script: “You will be walking 10 complete laps around the course, about 1/4 mile.  We would like 
you to walk at a normal pace you can maintain over the 10 laps.  After you complete the 10 laps I will tell 
you to stop, and measure your blood pressure and heart rate.  “STOP” symptoms Script: “Please tell me 
if you fell any chest pain, tightness or pressure in your chest, if you become short of breath or if you feel 
faint, lightheaded or dizzy, or if you feel knee, hip, calf, or back pain.  If you feel any of these symptoms, 
you may slow down or stop.  Do you have any questions?”  (Start walking when I say ‘GO’ and try to 
complete 10 laps at a pace you can maintain.  Ready, go.”) 
 
a.  Baseline heart rate:                                                            ____________bpm 
 
b.  Cross off as each lap is completed:                                   1 2 3 4 5 6 7 8 9 10   
 
c.  Number of laps completed:                                                ___________laps 
 
d.  Did participant complete all 10 laps                                  1. Yes      2.   No 
 
e.  Record time at 400m or at stop:                                        ____:_____.____ 
         (Min:sec.hundreths/sec) 
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ID_______________ 
 
 f.  Did the heart rate exceed 135 bpm at any time   1.   Yes     2.  No 
     during the 400-meter walk? 
 
 g.  Heart rate at 400m or at stop:     _____________bpm 
 
h.  Blood pressure at 400m or at stop:                                      ______/______mmHg 
 
 i.  Heart rate 2 minutes after completion of 400m walk:    _____________bpm 
 
 j.  Did the participant complete the 400-meter walk?    1.   Yes      2.   No  
  Reason walk was incomplete or not done: 
   Excluded based on criteria 
   Refused 
   Heart rate > 135 bpm during 2-minute walk 
   Heart rate < 40 bpm 
   Symptoms reported during walk: 
   Specify reason_________________________ 
   Stopped by technician: 
   Specify reason_________________________ 
   Other:  
   Specify reason_________________________ 
 
While you were walking, did you have any of the following symptoms? 
 
Chest pain?   Yes  No  Don’t Know 
Shortness of breath?  Yes  No  Don’t Know  
Knee pain?   Yes  No  Don’t Know 
Hip pain?   Yes  No  Don’t Know 
Calf pain?   Yes  No  Don’t Know 
Foot pain?   Yes  No  Don’t Know 
Numbness or tingling    
in your legs or feet?  Yes  No  Don’t Know 
Leg cramps?   Yes  No  Don’t Know 
Back pain?   Yes  No  Don’t Know 
Other symptoms*?  Yes  No  Don’t Know 
 *Please specify: _________________________________________________ 
   
   __________________________________________________ 
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WOMAN Phlebotomy/Processing Form  
DATE__________   Phlebotomist ID: _______                             ID: ____________      
PHLEBOTOMY 
Participant Questions: 
1.  Do you bleed or bruise easily? 
 No: ______ Yes: _______  Don’t Know: _________ 
2.  Have you ever been told you have a disorder related to blood clotting or coagulation? 
 No: ______   Yes: _______  Don’t Know: _________ 
3.  Have you ever experienced fainting spells while having blood drawn? 
 No: ______ Yes: _______  Don’t Know: _________ 
4.  Do you have diabetes? 
 No: ______ Yes: _______  Don’t Know: _________ 
5.  Are you fasting? 
 No: ______ Yes: _______  If yes, how long? ________________ 
Was any blood drawn: (circle one) Yes No   Time Drawn: _______________ 
 If no, reason not drawn: _________________________________________________ 
Venipuncture:   
Venipuncture time elapsed: _________________________minutes 
Time elapsed until tourniquet released: ____________________(2 min optimum) 
Quality of venipuncture: C (Clean) T (Traumatic - please specify) 
A.  Vein collapse B. Hematoma  C. Vein Hard to get D. Multiple sticks 
 E. Excessive duration of draw F. Leakage at venipuncture site 
Site of venipuncture: ________________________________________________________ 
Position of participant during blood drawing: supine  sitting 
Blood drawing: 
Blood Volume per Tube:  Fill (?)    Other (specify volume) 
1.  EDTA 10mL  ________________   __________________ 
2.  Serum 15mL   ________________   __________________ 
3.  Serum 10mL   ________________   __________________ 
4.  Na citrate 5mL  ________________   __________________ 
5.  Li Heparin 4mL  ________________   __________________ 
************************************************************************************* 
PROCESSING       Processor ID: ________________ 
Centrifuge after 30 minutes: 
Indicate after centrifugation complete whether plasma is Lipemic (L), Icteric (I), Hemolyzed (H), or clotted (C). 
Tube  (?) *   Suggested Aliquot  Blind 
  Done Lab Number vol(ml)  Tube  dupl. (?)  Comment  
#1 NMR EDTA (  ) L ______  2ml  Cryovial (  )            _________ 
#2 DNA EDTA (  ) S ______  1ml  Cryovial (  )            _________ 
#3 Extra EDTA (  ) S ______  1ml  Cryovial (  )            _________ 
#4 Extra EDTA (  ) S ______  1ml  Cryovial (  )            _________ 
#5 Na citrate (  ) V ______  1ml  Cryovial (  )            _________ 
#6 Na citrate (  ) V ______  1ml  Cryovial (  )            _________ 
#7 Serum (  ) H ______  3ml  Cryovial (  )            _________ 
#8 Serum L(a) (  ) H ______  1ml  Cryovial (  )            _________ 
#9 Serum CRP (  ) V ______  1ml  Cryovial (  )            _________ 
#10 Serum IL-6 (  ) V ______  1ml  Cryovial (  )            _________ 
#11 Serum Est. Met.(  ) I ______  1ml  Cryovial (  )            _________ 
#12 Serum TSH (  ) I ______  1ml  Cryovial (  )            _________ 
#13 Extra Serum(  ) S ______  1ml  Cryovial (  )            _________ 
#14 Extra Serum(  ) S ______  1ml  Cryovial (  )            _________ 
*L=Lipomed           V=University of Vermont               H=Heinz Lab  S=Storage 
                                                                             CBAL Use Only 
Received Date: _________________        Time: __________________         Frozen: _____________  
Comment: _________________________________________________________________________ 
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THE MODIFIABLE ACTIVITY QUESTIONNAIRE (MAQ) 
 
1. Please circle all activities listed below that you have done more than 10 times in the past year 
from _________________________ to _________________________. 
 
1  Jogging (outdoor, treadmill) 14 Football/Socer 27 Stair Master 
2  Swimming (laps, snorkeling) 15 Raquetball/Squash 28 Fencing 
3  Bicycling (indoor, outdoor) 16 Horseback Riding 29 Hiking 
4  Softball/Baseball 17 Hunting 30 Tennis 
5  Volleyball 18 Fishing 31 Golf 
6  Bowling 19 Aerobic Dance/Step Aerobic 32 Canoeing/Rowing Kayaking 
7  Basketball 20 Water Aerobics 33 Water Skiing 
8  Skating (roller, ice, blading) 21 Dancing (square, line, ballroom) 34 Jumping Rope 
9  Martial Arts (karate, judo, kendo) 22 Gardening or Yardwork 35 Snow Skiing (x-country) 
10 Tai Chi 23 Badminton 36 Snow Skiing (downhill) 
11 Calisthenics/Toning Exercises 24 Strength/Weight Training 37 Snow Shoeing 
12 Wood Chopping 25 Rock Climbing 38 Yoga 
13 Elliptical Trainer 26 Scuba Diving 39 Other 
40 Walking for Exercise (outdoor, indoor at a mall or fitness center, treadmill) 
 
List each activity that you circled in the “activity” box below, check the months that you did each activity over the past year and then estimate the 
average amount of time spent in that activity.  If participant did not participate in any activities, please check the box below marked none.  
None ? 
ACTIVITY 
A
ct
iv
ity
  #
 
JA
N
 
FE
B
 
M
A
R
 
A
PR
 
M
A
Y
 
JU
N
 
JU
L 
A
U
G
 
SE
PT
 
O
C
T 
N
O
V
 
D
EC
 
Average 
# of 
Times 
per 
Month 
Average 
# of 
Months 
Each 
Time 
                
                
                
                
                
                
                
                
                
                
                
2. Excluding time at work, in general how many HOURS per DAY do you usually spend 
watching television or walking on the computer? ________ hours 
 
3. Over this past year, have you spent more than one week confined to a bed or chair as a result 
of an injury, illness, or surgery? Yes _______  No _______ 
 If yes, how many weeks over the past year were you confined to a  
bed or chair? _______ weeks 
 
4. Do you have difficulty doing any of the following activities? 
 a. getting in or out of a bed or chair?   Yes _______  No _______ 
 b. walking across a small room without resting? Yes _______  No _______ 
c. walking for 10 minutes without resting?  Yes _______  No _______  
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5. Did you ever compete in an individual or team sport (not including any time spent in sports 
performed during school physical education classes)? Yes _______  No _______ 
 If yes, how many total years did you participate in competitive sports? _______ years 
 
6. Have you had a job for more than one month over the past year, from last _____ to this_____? 
 
List all JOBS that the individual held over the past 12 months for more than one month.        
Account for all 12 months of the past year.  IF unemployed/disabled/homemaker/student during 
all or part of the past 12 months, list as such and probe for job activities of a normal 8 hour day, 
5 day week. 
 
 Out of the total # of “hrs/day” the individual reported working at this “job”, how much of this time was 
usually spent sitting?  Enter this # in “hrs sitting” 
column, then place a check in the category that best 
describes their job activities when they are not sitting.  
Average Job Schedule Hrs. 
spent 
sitting at 
work 
Check the category that best 
describes job activities when not 
sitting 
 
 
 
 
 
 
 
 
 
Job 
Name 
 
 
 
 
 
 
 
 
Job 
Code 
 
 
Walk or 
bicycle 
to/from 
work 
 
 
 
Min/Day 
 
 
 
 
Mos/Yr 
 
 
 
 
Days/Wk 
 
 
 
 
Hrs/Day 
 
 
 
Hrs 
Sitting 
 
 
 
 
A 
 
 
 
 
B 
 
 
 
 
C 
          
          
          
          
 
 
Category A 
(Includes all sitting activities) 
Category B 
(Includes most indoor activities) 
Category C 
(heavy industrial work, outdoor 
construction, farming) 
Sitting Carrying light loads Carrying moderate to heavy loads 
Standing still w/o heavy lifting Continuous walking Heavy construction 
Light cleaning Heavy cleaning Farming 
Driving a bus, taxi, tractor Gardening Digging ditches, shoveling 
Jewelry making/weaving Painting/Plastering Chopping (ax), sawing wood 
General Office Work Plumbing/Welding Tree/pole climbing 
Occasional/short distance walking Sheep Herding Water/Coal/Wood Hauling 
 
 
JOB CODES 
Not employed outside of the home: Employed (or volunteer): 
1. Student 6. Armed Services 
2. Home Maker 7. Office Worker 
3. Retired 8. Non-Office Worker 
4. Disabled  
5. Unemployed  
 
 
 
 
 
Seven Day 
Physical Activity Diary 
ID______________________ 
 
Dates Recorded  
_____ / _____ / _____  to 
_____ / _____ / _____ 
 
Phone  (____)______________ 
    Reviewer Initials __________ 
 86 
  
 
Activity Diary Instructions: Only include activities or exercises 
you do for 10 minutes or longer*.  Please include only  the time 
that you are actually active.  Examples of physical activity 
includes brisk walking, gardening or yardwork, aerobics, 
swimming,  stairclimbing,  dancing,  golf,  weight training, etc. 
List each activity that you did during the day as well as the 
amount of time you spent doing that particular activity.   
 
Directions    
Please complete your log the week following your clinic visit. 
This log consists of two parts 1). the pedometer and 2). activity 
diary.  We are asking you to wear the pedometer and record 
your activities every day for a full seven-day period.  For each of 
the seven days, please check the day of the week (ex. Monday) 
and write in the date.  Each of the seven days is to be recorded 
on a separate sheet. 
 
Pedometer Instructions: The monitor is to be clipped snuggly to 
your clothes or on a belt at the waist.  First thing every morning, 
just before you put on the monitor, push the reset button and 
make sure the monitor reads “zero”.    Record the time you put 
on the monitor in your activity log and circle am or pm.  Keep 
the monitor on all day, except when swimming or bathing. 
Remove the monitor at night just before bedtime and record the 
number of steps per day along with the time that it was removed 
in the activity log and circle am or pm.  Please repeat these steps 
for the next seven days.   
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 Day 1: c c c c c c c 
                    Sunday           Monday          Tuesday         Wednesday       Thursday          Friday                Saturday 
 
Date: __ __ /__ __ / __ __  
           (month)             (day)                (year) 
 
Time you put the monitor on in the morning: __ __ : __ __ am or pm 
 
Time you took the monitor off in the evening: __ __ : __ __ am or pm 
 
 
 
 
 
 
 The number of steps taken today from the pedometer: ________________ 
 
Did you remove the monitor for longer than 30 minutes for any 
reason today such as bathing, swimming, or water aerobics?  If 
YES, please fill in the time that the monitor was taken off and 
the time it was put back on.   
Activity YES NO Time 
Monitor 
Removed 
Time 
Monitor 
Put Back 
On 
Bathing ? ? __ __ : __ __ 
am or pm 
__ __ : __ 
__ 
am or pm 
Swimming/Water 
Aerobics 
 
 
 
? ? __ __ : __ __ 
am or pm 
__ __ : __ 
__ 
am or pm 
 
Leisure Physical Activity Done Today for 10 minutes or more  
       
Activity/Exercise        Total Minutes/                 Activity  
                                       Day                              Code 
 
WALKING   ________  ________ 
 
2.  ___________________ ________  ________ 
 
3.  ___________________ ________  ________ 
 
4. ___________________ ________  ________ 
 
5. ___________________ ________  ________ 
 
6. ___________________ ________  ________ 
 
*NOTE: This form is replicated for an additional 6 days to obtain 7 days of 
pedometer step counts and reported leisure physical activity levels.   
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